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ABSTRACT 
 
A NOVEL MOUSE MODEL TO ELUCIDATE THE ORIGINS AND THERAPEUTIC 
SENSITIVITY OF TESTICULAR GERM CELL TUMORS 
 
Timothy M. Pierpont, Ph.D. 
Cornell University 2017 
 
Testicular germ cell tumors (TGCTs) are the most common malignancy among young men. These 
cancers are exquisitely sensitive to genotoxic chemotherapies, even after distant metastasis. A 
better understanding of the mechanisms underlying this chemosensitivity could improve 
treatments for more chemoresistant cancers. Because TGCTs arise from germ cells and contain 
cells with prominent pluripotent stem cell features, we hypothesized that specialized DNA damage 
response (DDR) properties associated with pluripotent stem cells might underlie their exquisite 
chemosensitivity. To test this hypothesis and to further elucidate the biology of these cancers, we 
generated a novel mouse model of malignant TGCTs. Tumorigenesis was induced by simultaneous 
cre mediated Pten inactivation and KrasG12D activation controlled by Stra8-cre, a germ cell-
specific cre recombinase. Approximately 75% of mice with both Pten and Kras alterations 
developed grossly apparent teratocarcinoma by five weeks of age. These tumors harbored both a 
teratoma component and malignant embryonal carcinoma (EC), a totipotent cancer stem cell 
(CSC) identified diagnostically by expression of OCT4, NANOG, and SOX2. Early neoplasms 
were also detected in testes as early as postnatal-day 3, and only 1-2 tumor initiation sites were 
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observed per testis, suggesting that tumor induction occurred prenatally. Indeed, lineage tracing 
analyses identified Cre-mediated excision in rare, isolated clusters of germ cells as early as 12.5 
post fertilization. Treatment of TGCT bearing mice with genotoxic chemotherapeutics resulted in 
significantly increased survival and reduced tumor burden. Most significantly, the EC cells were 
selectively depleted from the primary tumors of treated mice. These findings suggested these CSCs 
were uniquely sensitive to genotoxic chemotherapy, which may help explain why genotoxic drugs 
are so efficacious in treating this disease. To better understand how the CSCs were responding to 
chemotherapeutics, we established two EC cell lines from our mouse model. Both EC cell lines 
retained their ability to reproduce teratocarcinomas and exhibited increased chemosensitivity 
compared to differentiated cells derived from the same cell lines. Using these in vivo and in vitro 
models, ongoing research will continue to identify more specific mechanisms underlying the 
chemosensitivity in these cancers. 
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CHAPTER 1 
INTRODUCTION 
 
Testicular germ cell tumors (TGCTs) represent a rare success in the ongoing battle against cancer, 
as this highly aggressive solid cancer can be effectively treated in most patients. The drugs used 
to treat TGCTs work by damaging DNA to induce cell death, yet those same drugs are much less 
efficacious against most other forms of cancer. Understanding the basis for the impressive 
chemosensitivity of TGCTs requires a thorough understanding of germ cell development, germ 
cell and somatic cancers, DNA damage response (DDR) to treatment, and the role of stem cell-
like cells in tumor development and treatment response. Chapter 1 is a review of historically 
relevant and current knowledge in these areas which supports the importance of the findings 
unveiled in the chapters that follow. 
 
1.1 GERM CELL DEVELOPMENT 
With very few exceptions, all cells of the body harbor identical genetic information. Despite this, 
the cells of a multicellular organism display an immense phenotypic variation. In all mammals, 
development begins as a fertilized totipotent zygote, capable of differentiating into any of the 
unique and specialized cells necessary to maintain the maturing organism and its extraembryonic 
tissues. The phenotypic variation among cells is created through relatively small changes in gene 
expression, mostly regulated by transcription factors and other regulatory proteins and RNAs, as 
well as more global changes in gene expression facilitated by chromatin remodeling and changes 
in DNA methylation1. These changes in gene expression which are heritable by daughter cells are 
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known as epigenetic modifications. After a few rounds of division as a totipotent stem cell, the 
majority of cells of the early embryo lose their totipotent potential through these epigenetic 
modifications, and nearly all cells commit to increasingly specific and limited cell fates. Somatic 
differentiation is rarely reversed during development and is necessary to produce stable somatic 
cell lineages that ensure homeostasis of the mature organism. Germ cells, however, undergo a 
distinct, highly specialized maturation process which leaves these unique cells able to revert to a 
totipotent state such that they retain the potential to form an entirely new individual. The work 
described in this dissertation revolves around cancers arising from these particular cells. Thus it is 
important to begin where these cancers begin, within normal germ cell development, and where it 
goes awry. 
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Figure 1.1 Model of murine primordial germ cell specification and migration (Illustrations 
adapted from Saitou et al., 2012)2. PGC specification initiates around E6.25. Migration from the 
initial site of specification to the genital ridge begins around E7.5 with germ cells arriving at the 
genital ridge around E10.5, finally completing migration around E11.5. 
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1.1.1 Primordial Germ Cell Specification 
 
Development technically begins following oocyte fertilization by a single mature spermatozoon.  
After initial fertilization; the zygote divides four times to form a tight ball of totipotent cells called 
a morula. With the 5th morula division, the cells begin to lose totipotency, and the outer morula 
cells commit to trophoblastic lineages, while the inner cells commit to embryonic lineages3. At 
approximately three days after fertilization, tight junctions have formed which seal the outer 
morula while Na+/K+ pumps and aquaporins work to form a lumen at the center of the morula, thus 
signaling the transition to the blastocyst phase4. At this phase, the inner cell mass (ICM) forms 
within the lumen and contains the precursor cells for all of the embryonic cell lineages, while the 
outer cells contain the trophoblastic extraembryonic precursor cells. 
Mouse primordial germ cell (mPGC) specification initiates around 6.25 days post 
fertilization, after a substantial increase in cell number and blastocyst implantation. At this time, 
the cells of the extraembryonic ectoderm begin producing BMP4, an important signaling protein 
for several stages of development1,5. Surprisingly, although all cells of the epiblast have the 
potential to undergo PGC specification in response to BMP4 exposure, only a few hundred cells 
in the proximal posterior epiblast undergo this transformation6. The exact mechanisms controlling 
cell number are still unknown, however, the anterior signaling center, an area of the developing 
embryo located on the opposite side from PGC precursors, actively inhibits BMP4 signal 
induction, and is likely the main mechanism preventing the majority of epiblast cells from 
undergoing germ cell specification6.  
Expression of Wnt3 from the epiblast is also required to sensitize the epiblast cells to the 
BMP4 produced from the extraembryonic ectoderm, the combination of WNT3/BMP4 activation 
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drives the expression of three key transcription factors which facilitate susceptible cells’ 
commitment to the primordial germ cell fate. Mesodermal transcription factor T is expressed 
downstream of Wnt3, which in turn upregulates expression Prdm1(BLIMP1) and Prdm147. 
BLIMP1 then upregulates expression of Tfap2c (also known as Ap2y) and these three factors 
together bring about the transcriptional changes that drive primordial germ cell fate7,8. While this 
pathway is well characterized in mice, ethical concerns prevent similar studies being carried out 
to elucidate human germ cell specification. However, recent in vitro models have highlighted some 
of the key regulatory pathways in human PGC (hPGC) specification. 
Murine in vitro models of PGCs have been successfully generated using a stepwise 
differentiation process; the resulting cells are labeled mouse primordial germ cell-like cells 
(mPGCLC)9. These models faithfully recapitulate many of the germ cell transcriptional networks 
that have been verified using in vivo mouse studies, supporting the biological relevance of carefully 
interpreted data from such models7,8. Recently, a conceptually similar stepwise differentiation 
process was established for creation of human PGCLCs (hPGCLs)10. Based on the findings of the 
study, expression of mesodermal transcription factor SOX17, rather than T, appears to play a vital 
role in the hPGC specification as a master regulator of BLIMP110. This difference between hPGC 
and mPGC may help explain the complete lack of seminoma formation in mouse TGCT models 
which will be discussed later in this chapter10,11.  
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1.1.2 Primordial Germ Cell Migration 
 
In vertebrates, PGCs do not continue to proliferate immediately after specification but instead 
migrate from the initial site, in mammals, these early germ cells migrate to a somatic structure 
known as the genital ridge. The molecular underpinnings of germ cell migration in Drosophila and 
zebrafish are well established but comparatively little is known about what initiates and regulates 
germ cell migration in mice or humans5. In mice, germ cells initiate migration around E7.5, leaving 
the primitive hindgut and entering the endoderm. From there, they travel through the hindgut and 
mesentery, finally reaching the genital ridge by E11.5. KIT and its ligand are necessary for germ 
cell survival during migration and function as a mechanism for eliminating germ cells that do not 
properly migrate through the midline12. During and immediately after their migration, PGCs 
undergo significant epigenetic reprogramming, clearing histone markers and DNA methylation to 
remove imprinting and restore a totipotent state13. Much less is known about the molecular control 
of human PGC migration and reprogramming, but it appears to happen at similar developmental 
milestones as murine PGC migration and occurs between the fourth and tenth weeks in human 
fetal development13. After arriving at the genital ridge and completing epigenetic reprogramming, 
male germ cells undergo a mitotic arrest until after birth, while meiosis begins in females. 
 
1.1.3 Gonadal Sex Differentiation 
 
Before germ cells arrive at the genital ridge starting around day E10.5, the somatic portion of the 
gonad is just a thickening of the intermediate mesoderm with no sexual differentiation. As germ 
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cells arrive at the genital ridge, they infiltrate this tissue, transition from primordial germ cell into 
gonocyte, and begin to facilitate the development of either testes or ovaries14,15.  Development of 
the testis is set in motion by expression of SRY from around day 10.5 to 12.5 in mice (week 4-5 
in humans), with its main function being to up-regulate SOX9 in the pre-sertoli cells16. SOX9 then 
upregulates pathways which induce endothelial cell migration into the developing testis which is 
followed by vascularization and ultimately the formation of the sex cords16. Formation of the sex 
cords of the testis occurs around E12.5 in the fetal mouse, or in the 2nd month of human 
development, and marks the first appearance of sexual differentiation14,15.  
After an initial burst of proliferation at the genital ridge, male germ cells are quiescent until 
postnatal day 2, where they remain in the center of the sex cords surrounded by sertoli cells. At 
postnatal day 1, the gonocytes begin a short second migration from the center of the sex cords, 
through the sertoli cells, and flatten out against the basement membrane of the seminiferous tubule. 
Here, these germ cells differentiate into spermatogonial stem cells (SSC) and establish the 
polarization of the seminiferous tubule. In females, ovaries are characterized by a lack of sex cord 
formation, and less dramatic early morphological changes compared to the testis15. 
Development of the ovary was thought to be the default passive gonadal progression in the 
absence of SRY. However, RSPO1 and WNT4 are now known to be vital regulators of ovarian 
development through upregulation of the Wnt/β-Catenin pathway in mice and humans17,18. In part, 
this discovery came from studies aimed at understanding why, in rare cases, XX humans developed 
as phenotypic males. This rare event was eventually attributed to loss of function mutations for 
RSPO1 (Figure 2). While RSPO1 actively drives ovarian gonadal differentiation, earlier 
expression of SRY usually leads to repression of Rspo1 and β-Catenin through SOX9, to facilitate 
testicular development. In the absence of SRY, expression of RSPO1 is required to repress Sox9 
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and avoid testicular gonadal differentiation19. Despite active repression of the alternative pathway, 
incomplete gonadal development or development not matching genetic sex occurs with some 
frequency. This developmental aberration is associated with infertility as well as the development 
of TGCT in males (discussed more under etiology). Although current work and prior literature 
presented in this dissertation suggest that malignant TGCTs initiate before SSC specification, the 
protective mechanisms that prevent malignant transformation in later germ cells make it a relevant 
process to explain. 
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Figure 1.2 Crosstalk between ovarian and testis developmental pathways. (Figure adapted 
from Knarston et al., 201620). The diagram indicates that expression of SRY locks in male sex 
development by inhibition of the B-catenin pathway necessary for ovarian development. Later, 
SRY leads to SOX9 expression which inhibits RSPO1. Failure to inhibit these pathways result in 
ovarian development. Loss of RSPO1, however, allows testis development without SRY 
expression. The diagram shows current understanding of gonadal sex development choice at this 
stage and how both pathways are mutually exclusive, active processes. 
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1.1.4 Spermatogenesis 
 
Retinoic acid (RA) is a metabolite of vitamin A, also known as retinol, and is an important 
signaling molecule during development. In mice, during gonadal development, RA is produced 
from the mesonephroi, an early embryonic structure adjacent to the developing gonad21. RA 
synthesis initiates around E13.5 and diffuses into the gonads of both sexes21. In female mice, the 
presence of RA at E13.5 leads to expression of Stra821,22. Stra8 (Stimulated by Retinoic Acid 8) 
is a cytoplasmic factor whose expression is necessary for entrance into meiosis of both oogenesis 
and spermatogenesis23. 
In male mice, on the other hand, RA is actively degraded by increased expression of CYP26 
in the sertoli cells. During this time, the male germ cells undergo mitotic arrest until birth. This 
CYP26 activity prevents RA from initiating meiosis until postnatal day three or four, at which 
point RA degradation ceases due to downregulation of CYP2621. After downregulation of CYP26, 
RA stimulates postnatal expression of Stra8 and drives the transformation of pro-spermatogonia 
to spermatogonia. Interestingly, it is still not entirely clear which spermatogonial cells function as 
SSC. Based on experiments using an SSC-specific luciferase reporter, which expresses luciferase 
under the control of a 400bp portion of the Stra8 promoter, it was found that only a small 
population of Stra8 expressing spermatogonia had a high capacity to restore spermatogenesis upon 
transplantation into germ cell-depleted testes21,22. Proficient restoration of spermatogenesis reflects 
an ability to repopulate the SSC population and suggests that the 400bp marker is unique to SSCs. 
However, it is not yet known if those cells isolated by Stra8 expression, are SSCs, or 
spermatogonia from cysts (described below) which retained the ability to dedifferentiate to SSCs. 
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After gonocytes migrate to the basal lamina of the seminiferous tubule, they remain there 
throughout the life of the male, dividing asymmetrically as spermatogonial stem cells (SSC) and 
differentiating spermatogonia. However, despite their important role as the progenitors of all 
sperm, SSCs comprise a mere estimated 0.03% of all germ cells in the rodent testis24. Due to their 
extreme rarity, SSC properties have proven difficult to study. However, through a combination of 
in vivo, ex vivo, and in vitro analyses, there is a growing understanding of the molecular 
underpinnings for self-renewal, differentiation, and dedifferentiation of spermatoga25. SSC are a 
subset of spermatogonia type A (ASingle) cells, which undergo the first stages of differentiation by 
dividing four times with incomplete cytokinesis and are collectively referred to as a cyst25. 
Although it was believed that SSCs were limited to a portion of asymmetrically divided 
spermatogonial ASingle cells, it is now clear that many spermatogonia A cyst cells have the ability 
to disassociate and dedifferentiate back into individual SSCs rather than be committed to 
obligatory development towards meiosis25,26. 
After their first mitotic division with incomplete cytokinesis, spermatogonia A cells are 
referred to as Apaired rather than Asingle, and during the subsequent divisions, they are referred to as 
AAligned. After four mitotic divisions, at which point the matured cyst is comprised of 16 
spermatogonia AAligned with connected cytoplasm
25,26. During this progression, one notable change 
in gene expression is a loss of GFRA1 and gain of NGNA. These markers were used to help 
demonstrate the plasticity of Aaligned spermatogonia by showing that late stage, NGNa
+/GFRA1- 
can still contribute to the SCS population27. Furthermore, re-expression of Kit seems to initiate a 
key step in differentiation, and Kit+ spermatogonia cells from any stage show an impaired ability 
to regain the SSC phenotype27. These Kit expressing spermatogonia continue to differentiate as 
spermatogonial intermediates, and then spermatogonial B cells, as they enter pre-leptotene phase 
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of meiosis and transition to spermatocytes25. Spermatocytes undergo two rounds of meiosis, 
resulting in up to 64 mature gametes from the original spermatogonia Asingle
25. After the last stages 
of meiosis, spermatocytes begin a dramatic genomic remodel and morphological change to become 
mature spermatids and ultimately, mature spermatozoa, by way of a process whose details are 
beyond the scope of this dissertation. 
 
1.2 TESTICULAR GERM CELL TUMORS 
1.2.1 Germ Cell Neoplasia in situ 
 
Germ cell tumors comprise a heterogeneous array of well-characterized solid neoplasms that arise 
from germ cells28–30. TGCTs comprise the vast majority of germ cell tumors, and 98% of all 
testicular cancers, although ovarian and ectopic germ cell tumors are well documented28–30. While 
TGCTs are rare compared to other cancers, they are the most common malignancy among men 15 
to 44 years of age28,31. The majority of TGCTs arise from the same precursor lesion, germ cell 
neoplasia in situ (GCNIS), also known as intratubular germ cell neoplasia, undefined/carcinoma 
in situ (IGCNU/CIS)29. There is a fascinating and relevant history behind the discovery GCNIS as 
the precursor lesion of malignant TGCTs. 
In a historic paper, pathologist Dr. Skakkebæk proposed that GCNIS is the precursor lesion 
to TGCTs after he identified the pre-malignancy in the biopsies of two male infertility patients, 
both of whom later developed TGCTs32. Because of this connection, he initially termed the lesion 
carcinoma in situ (CIS), indicating a very early neoplasm growing “in its place.” The field initially 
dismissed the connection, but Skakkebæk went on to publish two landmark studies further 
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establishing this connection. The first of which analyzed biopsies of 555 male infertility patients, 
finding the precursor lesion in six33. Four of those six later developed invasive germ cell tumors 
within five years33. None of the patients without the precursor lesion developed TGCTs33. The 
second study analyzed the contralateral testis of 500 patients with TGCTs, in which 27 of them 
were found to have the precursor lesion34. Of these, eight were treated with aggressive 
chemotherapy for their initial malignancy, and none of those eight suffered a relapse34. Of the 19 
who did not receive aggressive treatment, seven later developed invasive TGCTs while all 473 
without contralateral GCNIS remained disease free for the 19 to 96 months following the biopsy34.
  
GCNIS is morphologically distinguishable from normal germ cell tubules by a thickened 
seminiferous tubule wall and abnormally large tetraploid germ cells32. The transformed germ cells 
are further characterized by increased expression of OCT4, NANOG, LIN28, TFAP2C, PLAP, 
PDPN, and KIT, and may have expression of SALL4 or DMRT135. These lesions have a 
hypomethylated genome with histone modifications (lack of repressive markers H3K9me2 and 
H3K27me3 and overrepresentation of activating markers H3K4me, H3K9ac, and H2A.Z) that 
make them more permissive to gene expression than the untransformed germ cells of normal 
tubules36. Importantly, GCNIS also expresses BLIMP1 and have similar permissive histone 
modification levels of H2K3me2s and H4K3me2s compared to PGCs, and seminomas (The most 
common TGCT, discussed below)37. These data support the idea of GCNIS as having a PGC or 
gonocyte origin, and its status as a precursor to mature TGCTs. 
While Skakkebæk and others have helped solidify GCNIS as the precursor to all malignant 
post-pubescent TGCTs, the original name, CIS, has continued to be controversial. Carcinoma in 
situ (CIS) implies an epithelial cell of origin, while the name intratubular germ cell neoplasia, 
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unclassified (IGCNU) implied a lack of knowledge about the lesion and the U is often 
misinterpreted as undifferentiated, undefined or unknown. After nearly a year of correspondence 
among experts in the field on the issue, the World Health Organization (WHO) consensus meeting 
in 2016 ultimately reclassified the lesion as germ cell neoplasia in situ (GCNIS)38. Along with the 
nomenclature change came a recommendation to change the broad classification of type I, II, or 
III TGCTs to the simplified and more descriptive categorization of TGCTs originating from 
GCNIS and TGCTs that do not29. 
  
1.2.2 Germ cell tumors derived from germ cell neoplasia in situ 
 
Based on WHO guidelines, germ cell tumors derived from GCNIS is the recommended category 
for TGCTs previously classified as type II. These germ cell tumors are the most commonly 
occurring germ cell malignancies, and occur in adolescent and young adult males (rates of 
incidence discussed more in depth in section 2.3.1). Amazingly, it is considered pathognomonic 
for all lesions in this category to harbor an extra copy of the short arm of chromosome 12, often 
as an isochromosome, i(12p). Because of the near-invariable presence of this chromosomal 
aberration, it is a useful diagnostic tool to identify germ cell tumors in this category as well as 
strong evidence for them sharing the GCNIS precursor lesion and similar pathogenesis. Germ cell 
tumors derived from GCNIS are highly aggressive metastatic malignancies that can be further 
subdivided into two categories, seminomas, and non-seminomas29,30. 
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Seminomas 
 
Seminomas, also known as pure seminoma or classical seminoma, are comprised of a mostly 
uniform cancer cell which resembles primordial germ cell morphology and has diagnostic 
expression profiles that are nearly identical to PGCs and GCNIS (Fig. 1.1). Importantly, these 
tumors are distinguishable from GCNIS and embryonal carcinoma (EC) by SOX17 expression10. 
The fact that SOX17 is implicated as a key regulator for specification of hPGCs supports the theory 
that these malignancies initiate during early embryogenesis10,11. Approximately 45-55% of all 
TGCTs are pure seminoma, while nearly all others are mixed nonseminomas39. These cancers tend 
to present as an enlarged testis or lump which is usually painless. From the initial site, they often 
metastasize through the lymphatics to nearby lymph nodes as well as the liver, lung, bones and 
other organs at later stages. 
 
Nonseminomas 
 
Comprising approximately 45% of TGCTs, these tumors tend to be very heterogeneous and more 
aggressive than seminomas39,40. They also tend to justify more aggressive treatments at advanced 
stages compared to seminomas41. Nonseminomas are divided into the four most commonly 
occurring subtypes: EC, teratoma, yolk sac or trophoblastic choriocarcinoma. Unlike seminomas, 
nonseminomas rarely occur in a pure form and are instead usually a mixed germ cell tumor, which 
is comprised of multiple GCNIS derived germ cell cancers types39. 
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Embryonal Carcinoma 
 
Embryonal carcinoma (EC) is a malignant totipotent cancer cell capable of differentiating into 
embryonic tissues, as well as extraembryonic yolk sac and trophoblastic tissues42,43. It tends to 
metastasize through the lymphatic system and to the lungs and is frequently more aggressive than 
seminomas40. Only 2-10% of all nonseminomas are a pure EC, but it occurs in 80% of all mixed 
germ cell tumors making it the second most commonly present germ cell cancer30. EC frequently 
occurs with teratoma components, which together form a malignant mixed nonseminoma, 
teratocarcinoma42,43. The discovery and early experiments of EC in mice played a critical role in 
advancing stem cell biology, the history, and implications of EC research are discussed in depth 
later. 
 
Postpubertal-Teratoma 
 
All teratomas are defined by the presence of cells resembling at least two of the three germ layers, 
mesoderm, ectoderm, and endoderm30. These tissues can occur as predominantly mature-like, or 
predominantly immature fetal-like in phenotype30. Postpubertal-teratomas arise from GCNIS and 
are frequently malignant, showing metastasis in 22-37% of all cases30. Although histologically 
identical, prepubertal-teratomas are benign, lack of i(12p), and are not believed to derive from 
GCNIS29,30. 
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Postpubertal-Yolk Sac Tumor 
 
Yolk sac tumors originate from extraembryonic trophoblast tissues. These tumors rarely occur in 
pure form and are present as a component in 40% of all non-seminomas. Both postpubertal and 
prepubertal-yolk sac tumors have identical histology comprised of a wide range of patterns that 
resemble normal yolk sac, allantois, and extra-embryonic mesenchyme. Postpubertal-yolk sac 
tumors, like postpubertal-teratomas, originate from the GCNIS precursor lesion, while 
Prepubertal-yolk sac tumors do not29,30. 
 
Choriocarcinoma 
 
Like yolk sac tumors, choriocarcinoma originates from extraembryonic trophoblast tissues. These 
tumors are a rare but highly malignant neoplasm. In pure form, it represents a mere 0.19% of all 
TGCTs but occurs as a portion of mixed germ cell tumors in about 8%29,30. Because this cancer 
spreads relatively early during tumorigenesis, often before discovery, most patients present with 
an advanced stage of this disease, and it, therefore, carries the worst prognosis10.  
 
1.2.3 Germ cell tumors unrelated to germ cell neoplasia in situ 
 
Following the revised WHO guidelines established at the 2016 consensus meeting, Type I and 
Type III germ cell tumors are now classified as germ cell tumors unrelated to GCNIS 29,30,38. Type 
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I consisted of TGCTs that arose during fetal and prepubescent life and offered no distinction 
between pre and postpubertal-yolk sac tumors or teratomas which, despite being histologically 
similar, have different genomic aberrations and very different progressions29,30. Germ cell tumors 
unrelated to GCNIS germ cell tumors unrelated to GCNIS have no known precursor lesion, and 
the initiation is believed to happen earlier in development than GCNIS, but the specific progression 
of the disease remains unknown44. These occur very rarely, at a rate of about 0.5 to 2.0 per 
1,000,000 in children, but are worth mentioning because most mouse models of TGCTs are more 
representative of prepubertal-teratomas (models discussed later)45. Spermatocytic tumors (also 
known as type III or spermatocyte seminoma) are a benign TGCT that occurs much later in life, 
around 52 years of age, and has no analogous lesion in women45. These neoplasms are believed to 
originate from spermatogonial stem cells in older men, likely initiated by gain of function 
mutations in FGFR3 or HRAS, followed by clonal expansion35,46,47. 
 
1.2.4 Epidemiology and Etiology of GCNIS Derived TGCTs 
 
The incidence of TGCTs has steadily increased for the past 30 to 40 years, especially in developed 
countries39. Importantly, the rate of increasing incidence is not equal across ethnic groups, which 
suggests there is not only a strong environmental component but also a genetic component to 
susceptibility as well31. In a study looking at changes in cancer incidence among people who 
immigrated to Sweden, it was discovered that the rate of TGCTs decreased after immigration, 
suggesting important environmental risk factors48. Other studies looking at familial risk factors 
found that TGCT risk comes from both environmental and genetic factors49. While an 
environmental influence on risk factor seems almost certain, no solid exogenous risk factors have 
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yet been identified. However, several diseases and genetic aberrations have been associated with 
increased risk of TGCT. 
 
1.2.5 Potential genetic risk factors and driver mutations 
 
Although it is clear that there exist important environmental risk factors for TGCTs, discovering 
them has proven elusive. Genetic risk factors and alterations have proven more amenable to 
elucidation. Interestingly, while prepubertal TGCTs are diploid, GCNIS derived TGCTs are 
aneuploid and tend to have reoccurring chromosomal rearrangements50. Furthermore, largely 
thanks to genome-wide association studies (GWAS), many genetic risk factors and potential driver 
mutations have also been identified. The combination of these findings is helping us unravel the 
molecular details of TGCT pathogenesis, the exact mechanisms, and timing of which remain 
unknown. 
 
Genomic instability in TGCTs 
 
All GCNIS associated TGCTs are aneuploid. Interestingly, as mentioned above, nearly all TGCTs 
that derive from GCNIS harbor a duplication of the short arm of chromosome 12, usually as an 
isochromosome (i(12p)), which is present in approximately 80 percent of seminoma and 
nonseminoma51. Most GCNIS are hypertetraploid, as are most seminomas, yet cells of GCNIS 
rarely contain an isochromosome of 12p35,51,52. This finding has led to the hypothesis that 
acquisition of i(12p) plays a key role in the transition from pre-malignant GCNIS to invasive 
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seminoma and nonseminomas. The most likely explanation of how an extra copy of 12p facilitates 
this step in the progression is that extra copies of genes contained on the chromosome fragment 
are sufficient to facilitate sertoli cell independence52. Supporting this idea, several genes on 12p, 
such Nanog, Stellar, Kitlg, and Kras2 facilitate maintenance of stemness, cell proliferation, and 
cell survival, some of which have been implicated as susceptibility genes of TGCTs in independent 
studies53. Importantly, these genes not only have copy number increased due to i(12p), but their 
expression is upregulated in invasive TGCTs compared to pre-invasive GCNIS54,55. Increased 
expression of these control genes could make it more permissive for transformed germ cells to 
survive outside of the tubule niche, thus implicating the underlying mechanisms for transition to 
invasive TGCT and explaining the near ubiquitous presence of i(12p) among invasive germ cell 
tumors. Although many gene mutations have been found in TGCTs, I will elaborate on only Kitlg, 
because of its high incidence of mutation in TGCTs, as well as Kras and Pten due to their high 
prevalence of the disease as well as their relevance to the work presented in this thesis. 
  
Kit 
 
The KIT protein is a receptor tyrosine kinase (also known as CD117) which dimerizes to activate 
its downstream cascade upon extracellular binding of its ligand, KITLG (Also known as STEEL 
or Stem Cell Factor, SCF)56. KIT is critical for a variety of stem cell development, including germ 
cells (See section 2.1). Kemmer et al. was the first to screen a cohort 54 seminomas for expression, 
sequence mutation, and constitutive kinase activity of KIT, discovering that 24.1% harbored 
activating point mutations in KIT57. Additional studies found that 21% of seminomas had 
increased copy number and expression of KIT, but it was rarely overexpressed in nonseminomas 
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or GCNIS58. Mutations affecting KITLG have also been associated with the development of 
seminomas through GWA studies59. The prevalence of KIT and KITLG mutations in seminomas 
suggests that having over-activation of its downstream pathways facilitate survival and 
invasiveness in transformed germ cell tumors similar to its effects on normal PGC survival and 
migration during development. 
 
Kras 
 
Kras is a GTPase, generally tethered to the plasma membrane. It is part of the RAS superfamily 
of proteins which interacts with c-Raf, stimulating the MEK/ERK pathway, and PI3K, stimulating 
the AKT pathway, along with other interactors, activation of these pathways play key roles in 
regulating cell proliferation, survival60. Importantly, RAS is a downstream target of KIT 
activation, as well as other RTKs61,62. KIT and RAS signaling are implicated as an important 
mechanism for transition into an invasive TGCT62. As mentioned above, this connection comes in 
part due to the extra copies of the Kras2 gene present in nearly all GCNIS derived TGCTs by way 
of i(12p). Aside from increased copy number of Kras in nearly all tumors, activating mutations of 
Kras and Nras have been found in TGCTs, mainly seminomas63. Kras was also found to be 
overexpressed in several different studies64. To induce tumors in our model (described in more 
depth below), a conditional transgene coding for a constitutively active G12D mutation was used. 
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Pten 
 
Aside from overexpression, or overactivation of genes that drive tumorigenesis, tumor suppressor 
genes are also reported to be mutated in TGCTs. Pten is a phosphatase that dephosphorylates 
phosphatidylinositol (3,4,5)-trisphosphate, helping to regulate the AKT pathway and serving as a 
tumor suppressor by negatively regulating cell survival and proliferation. Notably, it is one of the 
most commonly mutated tumor suppressor genes in cancers, and some SNPs are a risk factor for 
TGCT development65. Loss of Pten expression is also associated with the transition from GCNIS 
to invasive TGCT66. Along with the conditional activation of constitutively active Kras within the 
mouse model used in the presented studies, Pten is conditionally inactivated in the male germ cells 
of these mice. These alterations together drive tumorigenesis in the model. 
 
 
 
1.2.6 Disorders of Sex Development and Developmental Urogenital Abnormalities 
 
Disorders of sex development (DSD) are defined when a person’s phenotypic sex does not match 
their chromosomal sex, and usually resulting in infertility67. DSD often results from an inability to 
activate the canonical genetic gonad sex differentiation pathways, or a failure to repress the 
opposing pathways67. 66 genes involved in the regulation of gonadal sex differentiation appear to 
play a role in this disease68. Although most genes associated with DSD are not associated with 
TGCT formation, it has been proposed that TGCTs result from similar defects which also lead to 
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impaired spermatogenesis (infertility), cryptorchidism, hypospadias and inguinal hernias44,69. 
Testicular dysgenesis syndrome (TSD) is a notable model proposed as a unifying syndrome, which 
places more mild sex development abnormalities on a spectrum with DSD, and indicates an 
increasing risk of TGCT among more severe TSD cases44,70. This theory suggests that aberrant 
gonadal sex developmental may lead to malignant transformation of germ cells into TGCTs. This 
concept is important to understanding why malignant TGCT initiation is limited to early 
development.  
 
1.2.7 The high cure rate of TGCTs after platinum-based chemotherapy 
 
Before the use of cisplatin, TGCTs carried a terrible prognosis similar to aggressive somatic 
cancers with only 5% of patients surviving beyond five years after diagnosis with late-stage 
disease71. At that time, germ cell tumors were treated with dactinomycin, vinblastine, and 
bleomycin, the last of which is still part of the current treatment regimen71. In a 1980s landmark 
study, in which 50 metastatic TGCT patients received a novel combination therapy of vinblastine, 
bleomycin, and cisplatin, there was an astounding 85% survival rate and is now considered the 
cure for this formerly incurable disease72. Today, cisplatin, etoposide, and bleomycin (BEP 
protocol) remain the standard of care for TGCTs, and this treatment results in up to 80% survival 
for advanced metastatic disease, with a 96% rate survival at all stages71. 
 The key facilitator of this revolution in treatment came with the discovery of cisplatin. The 
platinum-based drug originated from a 1967 screen of electrolysis generated compounds that were 
tested for their ability to inhibit the growth of E. coli73. Cisplatin causes inter and intra-DNA-strand 
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crosslinks as its main mechanism of inducing double strand breaks and apoptosis74. Because 
cisplatin causes renal and neurotoxicity, alternative platinum-based drugs carboplatin, and 
oxaliplatin are increasingly used, which tend to be equally effective for treating most somatic 
cancers and can be given at higher doses due to lower side effects75. Surprisingly, cisplatin is still 
the most efficacious platinum-based drugs against TGCTs, despite its greater toxicity, and is 
therefore still used in nearly all TGCT chemotherapy protocols76. 
 Cisplatin is given with both etoposide and bleomycin as the standard of care treatment for 
TGCTs. Etoposide is a topoisomerase II inhibitor, which also induces double strand DNA breaks 
leading to DNA damage and apoptosis. The topoisomerase II enzyme is necessary to release the 
tension of the supercoiled DNA caused by the helicase-mediated unwinding of DNA during 
replication. To do this, it first cuts and then uncoils double stranded DNA, before ligating both 
strands of DNA back together. Etoposide was first synthesized in 1967 from a class of toxins 
known as podophyllotoxins, derived from Podophyllum or wild mandrake plant77. Etoposide binds 
to topoisomerase II, and does not interfere with endonuclease activity of the enzyme, allowing the 
cuts to be made, but the drug does prevent the ligation step, thus facilitating the double strand 
break77. Bleomycin was isolated from Streptomyces verticillus in 1966 as a complex glycopeptide 
that had antibiotic properties78. Surprisingly, the exact mechanism by which the drug acts is still 
unknown. It is known that the drug acts directly on DNA, and utilizes a redox-active metal ion of 
iron or copper to induce the double strand breaks79. 
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1.2.8 Current mouse models of TGCTs 
 
The TGCT mouse model used to generate the data presented in Chapters 2 and 3 relies on two 
oncogenic events, mediated by Stra8-cre recombinase activity, which induces teratocarcinoma 
formation. Malignant transformation is driven by inactivation of tumor suppressor Pten, and 
simultaneous expression of constitutively active KrasG12D. This model is described in more depth 
within the data chapters. However, it is worth noting the alternative mouse models of TGCTs as 
they produce teratomas, rather than the more malignant teratocarcinoma, and are less characteristic 
of GCNIS derived TGCTs.  
 The original mouse model of TGCTs is the spontaneous formation of teratomas in 129 
inbred mice. Discussed in other portions of this dissertation, these tumors also rarely contained EC 
which was used in the early experiments of the disease80. Additionally, inbred 129 mice that are 
P53-/- develop teratomas at an increased rate81. Primordial germ cell-specific inactivation of PTEN 
starting from E9.5, facilitated by TNAP/Cre, leads to germ cell depletion and increased teratoma 
formation82,83. The Ter mutation in DND (DNDTer/Ter) also increases the rate of teratoma formation, 
as does consomic substitution of Chr19 from MOLF strain mice and genes on Chr19 appear to 
enhance tumor formation in normal 129 strain mice, as well as DNDTer/Ter84,85. Importantly, both 
of these mutations are only known to enhance tumor formation in 129 strain mice84,85.  
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1.3 THE DNA DAMAGE RESPONSE, CHEMORESISTANCE, AND 
CHEMOSENSITIVITY 
 
Genome integrity is necessary for the survival of all cellular life and ensures that genetic material 
is reliably passed to daughter cells, and from one organism to its offspring. DNA, however, 
encounters a continuous assault of potentially mutagenic DNA damage from both normal cellular 
function, as well as exogenous sources. The initial DNA damage response (DDR) is the detection 
of a break or adduct in the DNA, usually resulting in activation of kinases ATM (which responds 
to double strand breaks) or ATR (which responds to single stranded DNA)86. The activation of 
ATM and ATR leads to cell cycle checkpoint activation, thus halting or slowing the cell cycle 
while also signaling to downstream effectors to repair the damage, or if the damage is too 
extensive, to enter senescence or undergo apoptosis. While DDR pathways are critical for 
maintaining homeostasis and preventing genomic instability which can lead to cancer, these 
pathways are also a pivotal determinant of genotoxic chemotherapeutic sensitivity of all forms of 
cancers. 
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1.3.1 Mutations in DNA damage response pathways lead to chemoresistance 
P53 is one of the most commonly mutated genes in cancers, and loss of P53 function is associated 
with increased chemoresistance87. Gains and losses of other genes that perturb DDR pathways are 
also associated with tumorigenesis, and because many modern chemotherapeutics work by 
damaging DNA to facilitate cancer cell death, disruption of DDR pathways often leads to 
chemoresistance88,89. Genotoxin induced cell death in cancer can be circumvented if cancer cells 
obtain increased DNA repair, or can avoid cell cycle arrest and apoptosis.  
 
DDR as tumorigenesis barrier 
 
The DDR not only protects our genome from the constant barrage of DNA-damaging insults, but 
it also plays an important role as a barrier to tumorigenesis. Oncogene activation drives 
tumorigenesis and also rapidly increases DNA damage through double strand breaks and increased 
ROS88. In response to this damage, even during early tumorigenesis, somatic cancers exhibit 
constitutively active DDR as evidenced by phosphorylated CHK2, ATM, and yH2AX which often 
persist at late stages90. The exact source of the damage is still unknown but is likely aberrant 
replication structures and DNA damage caused by unscheduled replication brought about by the 
oncogenic activation. This hypothesis is supported by the observed activation of phosphorylated 
P53, CHK1, and y-H2AX, in U-2-OS cell lines after oncogenic activation of either E2F1, Cdc25a, 
or Cyclin E90. 
 While DDR activation in response to aberrant proliferation acts as a barrier to 
tumorigenesis, it also causes selective pressure to mutate genes responsible for maintaining 
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checkpoint activation and senescence. Indeed, cell cycle progression despite persistent DNA 
damage occurs in many cancers, suggesting failed checkpoint activation88,91. Importantly, P53 is 
necessary for maintaining cellular senescence and would, therefore, often be subjected to these 
selective pressures which may explain why it is the most commonly mutated gene in somatic 
cancers88,91. Loss of proper DDR leads to increased genomic instability, observable by the increase 
in mutations and genomic abnormalities in later stage cancers90. Importantly, GCNIS, the early 
stage TGCT lesions described earlier, do not show the constitutive activation of the DDR that is 
seen in most somatic cancers92,93. This lack of DDR activation in TGCTs avoids selective pressures 
to mutate genes that control proper DDR and checkpoint signaling, and it is a likely explanation 
for the comparatively low mutation rate of DDR genes including P53 in TGCTs.  
 
Chemoresistance due to disruptions in apoptotic pathways 
 
P53 is the master regulator of cell cycle arrest and cell death, acting as a barrier to tumorigenesis 
and an important determinant of therapeutic responses to genotoxic chemotherapies after 
tumorigenesis. Unfortunately, P53 mutations range as high 50% frequency among certain cancers 
and are the most common gene mutations in cancers overall94. While P53 mutations can cause 
defects in signaling for cell senescence and apoptosis, downstream players in these pathways are 
also commonly mutated in chemoresistant cancers.  
Mitochondrial-dependent apoptosis is one of the main pathways of DNA damage-induced 
cell death, also known as the BCL-2 regulated apoptotic pathway. This pathway is regulated by 
anti-apoptotic BCL-2 like proteins, and pro-apoptotic BH3-only proteins (so named for the 
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presence of conserved BH3 domain) which include PUMA, and NOXA. PUMA and NOXA are 
p53 regulated BH3 family proteins which induce apoptosis in response to DNA damage by 
interacting with BCL-2 family proteins and inhibiting their ability to negatively regulate pro-
apoptotic factors BAK and BAX. Without inhibition, BAK and BAX can localize to the 
mitochondria and permeabilize the membrane allowing the release of cytochrome c95. Once 
released, cytochrome c activates the caspase cascade and thus initiates apoptosis.  
Many cancers hijack the proteins that regulate apoptosis, allowing them to evade 
programmed cell death and thus conveying chemoresistance. Overexpression of BCL-2 family 
proteins correlates with chemoresistance and is a potential target for combination therapies96–98. 
Pushing the apoptosis pathway in the other direction can have beneficial therapeutic outcomes, 
further emphasizing the importance of these pathways in chemoresistance. For instance, 
expression of BH3-only proteins PUMA, NOXA, and BIM confer sensitivity to chemotherapeutics 
resulting in a better prognosis in chronic lymphocytic leukima99. Caspases can be divided into two 
main groups, initiator capsases-2, -8,  and -9, which help regulate the choice of apoptosis, and 
effector caspases-3, -6, and -7 which drive apoptosis after the cell fate has been chosen100. 
Mutations in caspase proteins are also associated with chemoresistance. Nonsense mutations in 
caspase-8 and loss of its expression are associated with increased chemoresistance in a variety of 
cancers, which can be at least partially re-sensitized by re-expression of the protein101. Reduced or 
absent caspase-3 expression was found also found in 75% of breast cancer cell lines and freshly 
isolated samples, suggesting a loss of caspase-3 expression contributes to breast cancer cell 
survival and resistance to apoptosis102. Taken together, it is clear that loss of canonical apoptotic 
pathways can, and do, play a role in the loss of chemosensitivity of many cancers. 
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Chemoresistance due to increased DNA damage repair 
 
A cell’s ability to repair damage caused by genotoxic chemotherapies directly impacts its response 
to those drugs. Cisplatin, carboplatin, and oxaliplatin are platinum-based therapeutics that are used 
against a wide range of cancers. They work primarily by forming DNA intra- and interstrand 
crosslinks. Several key repair pathways play a role in resolving the damage caused by these drugs: 
Homologous recombination (HR), nucleotide excision repair (NER) and DNA mismatch repair 
(MMR)103. Defects and reduced expression of MMR genes MLH1 and MLH2 are associated with 
increased chemoresistance, likely due reduced ability to detect, and respond appropriately to, the 
DNA lesions caused by platinum-based chemotheraputics104,105. NER, on the other hand, is the 
primary pathway responsible for removing the crosslinks formed by platinum-based drugs. 
ERCC1 and XPF form a nuclease complex which, along with ERCC4, facilitates the excision of 
the crosslink, which is followed by complete repair of the break. ERCC1 and XPF expression 
levels are prognostic for chemosensitivity103. In a study of 60 patients with locally invasive cervical 
squamous cell cancer, 86.21% patients with low mRNA levels of ERCC1 had a complete response 
to cisplatin-based therapy, while only 19.36% of patients with high mRNA levels showed complete 
response106. In a separate study, ERCC1 expression was evaluated immunohistochemically in 
paraffin-embedded tumors107. Samples were collected from 101 patients diagnosed with epithelial 
ovarian cancer before treatment. These patients were then treated with carboplatin-paclitaxel 
combination therapy. ERCC1 expression positively correlated with resistance to treatment, and 
75% of tumors expressing ERCC1 were resistant while only 27% of tumors which did not show 
ERCC1 expression were resistant107. HR is a pivotal player in repairing interstrand crosslinks 
mediated by Fanconi Anemia and BRCA proteins. Epithelial ovarian cancers have a high incidence 
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of platinum drug sensitivity which has been linked to the high frequency of HR defects of the 
cancers108. 
 
1.3.2 Other mechanisms of chemoresistance 
 
Aside from alterations in the DDR, drug resistance in somatic cancers often occurs from three 
other well-characterized mechanisms. These include increased cellular export of the drug, an 
increase in molecules that can render the drug less reactive, and alterations to the cellular 
components targeted by the drug.  
 
Drug Efflux 
 
The ability to clear a drug from a cell, or prevent its accumulation, is a cause of both primary or 
acquired multi-drug resistance. The major mechanism for this type of resistance is a family of 
multidrug exporters named ATP-Binding Cassette (ABC) transporters109. These are a tissue 
specific set of active transporters that can pump a variety of molecules, including 
chemotherapeutics, out of the cell against its concentration gradient109. A recent study of 
osteosarcoma cell line OS-65 found increased resistance to a variety of chemotherapeutics within 
a subpopulation of the cultured cells110. This subpopulation was found to harbor increased 
expression of ABCG2, ABCB1/MDR1, and ABCB5 transporters110. ABCC1 and ABCC3 are also 
overexpressed in many breast cancer cell lines, the knockdown of which can cause increased 
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chemosensitivity111. Similar findings of increased chemoresistance associated with increased 
expression of ABC transporters were found in glioblastoma, pancreatic, and colorectal cancers112–
114. Targeting these pathways has become an area of intense clinical interest in hopes of using 
combination therapy to sensitize certain resistant cancers115. 
 
Drug Detoxification 
 
The increase in two different proteins accounts for the majority of drug detoxification induced 
chemoresistance, glutathione S-transferase (GST), and dihydropyrimidine dehydrogenase (DPD). 
GST catalyzes the joining of glutathione with a variety of exogenous sources, including many 
platinum-based chemotherapeutics, which makes them accessible to ABC transporters. Some 
studies suggest that the conjugation activity of GST may not be the primary mechanism of 
resistance, but those, and others find that increased GST expression does contribute to 
chemoresistance116. One study took biopsies before treatment from 61 patients with primary 
ovarian cancer. 10 out of 11 tumors from cancers that were positive for GST-π were later found to 
be resistant to cisplatin-based treatment, while only 6 out of 17 GST-π negative tumors were 
resistant117. In a separate study of 107 patients with colorectal cancer treated with oxaliplatin, three 
common polymorphisms of GST known to decrease the proteins’ function were associated with 
increased patient survival. Higher expression of DPD, on the other hand, plays a key role in the 
catabolism of fluorouracil (5-FU) and is highly associated with resistance to the drug118. 
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Alteration of drug target 
 
Another mechanism of chemoresistance occurs when cancer cells have altered variants of the 
cellular component that the therapeutic drug targets. The most relevant examples to this 
dissertation are alterations of topoisomerase-II, is the known target of etoposide, described in 
Section 1.2.7. Etoposide inhibits topoisomerase-II, allowing the endonuclease activity of the 
enzyme, but blocking the ligation step, ultimately leading to the DNA damage which induces 
apoptosis as an effective chemotherapy for many cancers. Altered expression of topoisomerase-II 
isoforms is associated with altered sensitivity to etoposide and other topoisomerase inhibitors119. 
For instance, in several melanoma cell lines, increased topoisomerase II activity directly correlated 
with increase etoposide resistance120. 
 
1.3.3 Uncommon occurrences of TGCT chemoresistance mechanisms 
 
Although TGCTs are considered curable, even after distant metastasis, rare chemoresistant 
variants of the disease do occur. These mechanisms of resistance are often similar to resistance in 
somatic cancers, but at a much lower frequency. Most notable is the comparably low rate of P53 
and other DDR gene mutation in TGCTs121. Although almost non-occurring in random panels of 
TGCTs, P53 mutations were found in 5 out of 28 chemoresistant TGCTs122. Higher levels of P21, 
an important cell cycle regulator, were more highly expressed in chemoresistant EC cell lines and 
tumors, compared to their chemosensitive counterparts123. Within a panel of 35 chemoresistant 
TGCTs, MMR deficiencies, BRAF mutation (V600E), and microsatellite instabilities were all 
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increased compared to 100 chemosensitive controls124. The fact that DDR mutations are rare in 
TGCTs, yet do cause chemoresistance when they occur, further supports the idea that the lack of 
DDR during early tumorigenesis of TGCTs avoids a key step in selecting for the DDR mutations 
that regularly occur in somatic cancers. The avoidance of chemoresistance inducing mutations is 
likely to play an important role in keeping TGCTs sensitive to genotoxic chemotherapy drugs. 
However, there is also evidence that germ cells, and other pluripotent cell types, have a unique 
DDR that makes the hypersensitive to genotoxic DNA damage as detailed below. Because TGCTs 
arise from germ cells and have many similar phenotypes to other pluripotent cells, they likely share 
some of the same hypersensitivity mechanisms. 
 
1.3.4 The hypersensitive DDR of pluripotent stem cells 
 
Germ cells protect the genome that is to be passed to future generations and utilize a proficient 
DDR to avoid deleterious mutations from entering the germline. Other pluripotent cells, such as 
cells of the inner cell mass, or pluripotent cells that only exist in vitro, like embryonic stem (ES) 
cells and induced pluripotent stem (iPS) cells, all share certain similar properties. All of these cell 
groups have a unique DDR compared to somatic cells and tend to apoptosis at a lower threshold 
of DNA damage, likely to limit the chance of passing on deleterious mutations to a larger number 
of daughter cells, or offspring in the case of germ cells125,126. Less evidence exists regarding 
TGCTs DDR. However, sharing these the same mechanisms would help explain why TGCTs have 
such a positive response to genotoxic chemotherapies. 
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 Apoptosis, senescence, and differentiation are all DDR mechanisms employed to prevent 
or limit pluripotent cell proliferation. Although ES cells and iPS cells have increased DNA damage 
repair which leads to a more robust resolution of DNA damage compared to their differentiated 
counterparts, they also trigger apoptosis at lower thresholds of damage125,126. One aspect of this 
hypersensitive response is the fast induction of P53-dependent apoptosis in ES cells after DNA 
damage. In most cells not committed to apoptosis, BAX is cytosolic, and only after sufficient DNA 
damage is it activated to induce oligomerization and localization to the mitochondrial membrane 
where it facilitates the release of cytochrome c and induces apoptosis95. In human ES cells, 
however, BAX is already activated and primed at the golgi where it remains ready to relocate to 
the mitochondria at all times127. Importantly, this primed BAX phenotype does not remain after 
ES cells differentiate127. An additional mediator of hypersensitivity in ES cells is a reduced or 
absent G1 checkpoint. The G1 checkpoint is critical to ensure DNA replication does not begin if 
unrepaired DNA damage is present, thus preventing additional damage and genomic instability. 
Human ES and iPS cells, however, do not activate the CHK1 kinase after induction of replication 
stress and tend to induce apoptosis instead128. Human ES and iPS cells also fail to activate proper 
G1 checkpoints following irradiation and instead commit to apoptosis at a higher rate at compared 
to their differentiated counterparts125. Mouse ES cells appear to lack a G1 checkpoint which, 
similar to hESCs, results in elevated levels of DNA damage induced apoptosis compared to 
somatic counterparts129. 
 Differentiation in response to DNA damage is another unique response of pluripotent cells. 
Nanog is a necessary transcription factor required to maintain the pluripotency state of a cell130. In 
mouse ES cells, P53 binds to the Nanog promoter, in a DNA damage-dependent manner, and the 
resulting loss of Nanog expression induces differentiation131. Loss of Oct4 expression, another key 
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pluripotency transcription factor, also induces P53 mediated differentiation of embryonic stem 
cells132. These findings not only show a mechanism to limit pluripotent stem cell proliferative 
capacity after damage but demonstrate tightly woven DNA damage and pluripotency networks 
within these cells. This evolved interplay of these two complex cellular pathways likely helps 
ensure that cells attaining potentially harmful mutations will lose the indefinite proliferative 
capacity normally associated with pluripotent stem cells. 
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1.4 CANCER STEM CELLS 
 
The CSC theory is rooted as far back as the mid-1800s. During this period, German pathologists 
Rudolf Virchow and Julius Cohnheim first postulated the embryonic rest theory which postulated 
that cancer might arise from embryonic remnants, or cells left over from embryogenesis, which 
retained embryonic properties133. Over the decades, the theory had many key contributions, most 
relevant to this dissertations was the discovery that single EC cells from mice could regrow entire 
teratocarcinoma43. Since those experiments, a steady trickle of findings has become a flood of 
evidence which supports the existence and importance of CSCs in a variety of cancers. From this 
growing field, a well-defined yet still controversial model of CSCs has emerged. 
 
1.4.1 Clonal vs. cancer stem cell model of cancer 
 
The most widely accepted theories of cancer growth and heterogeneity are depicted in a key 2001 
Nature review (Fig. 1.4)134. In the stochastic model of cancer, most cancer cells can divide 
extensively and create new tumors while mutating to form tumor heterogeneity. In the CSC theory 
of cancer, while the tumor cells also have mutations and are heterogeneous, only a small population 
of cells can divide extensively and form new tumors. This limited population of cells is referred to 
as cancer stem cells, (also called tumor-propagating cells or tumor initiating cells) which fit the 
definition of normal stem cells in that they can self-renew and differentiate but in within the context 
of continued tumor progression rather than homeostasis.  There is evidence to support both models, 
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but realistically both apply to different extents, in a variety of cancers. The first clear support for 
the modern CSC theory can be traced back to one defining study in leukemia. 
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Figure 1.4 Graphical depiction of classical and cancer stem cell models of cancer. (Figure 
adapted from Reya et al., 2001134)Graphical representation of the classical model of cancer (Left), 
in which all cancer cells have the ability to divide indefinitely versus the CSC model of cancer 
(Right) in which only a very small population of cells have the ability to divide indefinitely. 
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  It has been known since the 1960s that only a subpopulation of leukemic cells would grow 
and form colonies, but it was not known from these studies if all cells had a rare chance to begin 
proliferation, or if only a subset of cells had this potential134. These two undetermined possibilities 
highlighted the key distinction between the classical and CSC model of cancer respectively. A 
study was done in 1997 which determined that acute myeloid leukemia stem cells could be isolated 
as CD34+ CD38- using FACS, thus confirming the idea that only a small population can divide 
extensively, rather than all cancer cells having a chance of doing so135. Since then, many studies 
have identified CSC populations in many solid cancers, contributing to the growing excitement 
that CSC-targeted treatments could lead to higher cure rates in a variety of cancers. 
 
1.4.2 The hope and controversy of CSC-targeted therapy 
 
The CSC theory of cancer is intensely alluring due to advances in treatment prospects as well as a 
valuable model for recurrence and metastasis. After treatment, there is often an initial response 
measured by reduction of bulk tumor, yet many patients relapse months or years later, ultimately 
succumbing to the disease. The CSC theory offers a potential explanation for relapse if CSCs are 
more resistant to canonical treatment. Even if a small number CSCs evade chemotherapy, it still 
leaves the malignancy able to regrow and metastasize (Fig. 1.5). Most importantly, targeting those 
CSCs specifically, in combination with broader treatments, would reduce the risk of relapse and 
perhaps make the disease curable. Indeed, several studies discussed in the next section have found 
that the percentage of CSCs often increases following conventional treatment, suggesting those 
cells are evading those therapies. 
41 
 
Figure 1.5 Cancer stem cell model and treatment response. (Figure adapted from Das et al., 
2008136). Graphical depiction of the possible role of CSCs in tumor recurrence following 
conventional cancer therapies. Alternatively, depicted on the lower pathway, a therapy directly 
targeting CSCs may cause loss of tumor malignancy and ultimately higher cure rates. 
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Despite the hope of better cancer treatments, there are some important caveats to the CSC 
theory of cancer. A portion of the controversy revolves around the nomenclature itself. The term 
CSC describes any cancer cell that can self-renew as well as differentiate into the other cellular 
phenotypes of that cancer. However, it is often mistakenly thought that the term implies that CSCs 
arise from a stem cell origin, or that the CSC is expected to possess similar phenotypes as normal 
stem cells, such as similar population sizes or consistency of markers. While CSCs certainly might 
arise from stem cells, and often have phenotypes comparable to stem cells from their tissue of 
origin, this is not necessarily the case and should not be implied by the term CSC. While 
clarification of nomenclature is necessary to avoid confusion, they do not pose concerns for the 
validity of CSC-targeted therapies137. 
 More relevant are concerns regarding the prevalence of CSCs and whether they are a 
sufficiently stable population of cells to be irradicated by targeted drugs. It is clear that some 
cancers have a high population of cells that can propagate tumors, rather than a small population 
of CSCs. One study found that 28% of melanoma cells obtained from patients’ cancer were able 
to propagate tumors and divide indefinitely138. Furthermore, the researchers sorted tumor cells 
based on 22 different cell markers but were unable to distinguish any subpopulation of cells 
without a tumor-propagating phenotype, which provides evidence against the CSC model. Other 
studies find that the CSC population is not necessarily well defined, suggesting that targeted 
therapies may work for a more limited range of cancers than hoped. Boiko et al. found that CD271+ 
tumor cells isolated from melanoma patients were able to form tumors in immunocompromised 
mice, while CD271- cells rarely did (70% vs. 7% engraftment success respectively)139. However, 
they concluded that the CSC population ranged from 2.5% to 41%, suggesting extreme variation 
in the population depending on the disease stage and the individual. Despite this conflicting 
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evidence, the CSC field of cancer research has rapidly increased over the recent decade, unveiling 
an overwhelming amount of evidence that CSCs exist in many cancers and that they appear to play 
a role in chemoresistance and disease progression. 
 
1.4.3 Somatic cancer stem cells and their therapeutic impact 
 
Acute Myelogenous Leukemia (AML) and Chronic Myelogenous Leukemia (CML) 
 
Leukemia is the uncontrolled proliferation of hematopoietic cells, generally arising from the 
aberrant self-renewal of hematopoietic stem cells. AML and CML are two well-characterized types 
of leukemia. As the name suggest, AML progresses rapidly as cells of the hematopoietic system 
fail to differentiate. The cure rate is approximately 35% to 40% in patients under 60, but only 5% 
to 15% survival for patients over 60, with older patients having a median survival of just 5 to 10 
months140. In part, the poor survival among older patients is due to lack of efficacious treatments 
with a low enough toxicity to use safely. CML, on the other hand, has poorly differentiated 
hematopoietic cells which may appear normal, and be somewhat functional which allows the 
disease progress considerably slower. Bone marrow transplant is often a curative treatment for 
CML, although Imatinib, an inhibitor of the constitutively active tyrosine kinase fusion protein 
BCR-ABL which that is frequently expressed after a chromosomal translocation between 9 and 22 
that occurs in most CML patients, produced exceptional 89% five-year survival rates141. Aside 
from Imatinib and bone marrow transplants, both AML and CML are also treated with genotoxic 
chemotherapy drugs. 
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As mentioned above, CSCs of AML were convincingly identified in 1997 as a population 
of CD34+ CD38- cells135. Similarly, hematopoietic stem cells (HCS), and CML CSCs, can also be 
identified based on CD34+ CD38- CD90+. This population was initially demonstrated by only 
those cells having the ability to repopulate nonobese diabetic–scid/scid mice in a lympho/myeloid 
assay142,143. It suggests that HCS are the CSC progenitor cell, or that at least two cell types share 
some phenotypes. Indeed, AML and CML CSCs have similar mechanisms of surviving genotoxic 
chemotherapies as compared to HCS, including quiescence which avoids induction of damage that 
usually occurs in proliferative cells143.  An additional study utilized a NOD/SCID/IL2rγnull mouse 
model of human AML to demonstrate that not only does quiescence offer a protective mechanism 
for AML CSCs, but the cells can also be re-sensitized to chemotherapy by inducing proliferation 
using granulocyte-colony stimulating factor144. Currently, work to generate targeted therapy 
against leukemia stem cells includes targeting unique membrane proteins, disrupting the CSC 
niche, and differentiation therapies145–147. 
 
Breast Cancer 
 
Unlike leukemia cancer stem, the majority of solid CSCs have yet to be confidently characterized 
and are often not easily isolated by cell surface markers. Breast CSCs were the first solid somatic 
CSC to be identified, although the populations also have a great deal of heterogeneity. Initial CSC 
identification came from a comparison of nine human breast cancers grown as patient-derived 
xenografts. After isolating and transplanting many different cell populations from these nine 
samples, researchers found that only CD44+ CD24-/low ESA+ cells were able to form tumors in 
NOD/SCID mice even with as few as 100 cells transplanted148. While all identified breast CSCs 
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have been CD44+ CD24-/low, ALDH1, EpCAM, and CD48f have all been shown to identify 
additional sub-populations149. 
 Like most somatic CSCs, breast CSCs appear to be more resistant to conventional 
treatments compared to the bulk tumor. The best evidence of CSC chemoresistance comes from 
studies finding increased CSC populations in tumor biopsies from breast cancer patients after 
receiving platinum-based treatments compared to their pretreatment biopsies150,151. Although 
many chemotherapeutics and targeted treatments exist, radiation therapy remains an important 
component of breast cancer treatment, especially at earlier stages152. However, like untransformed 
mammary stem cells, breast CSCs have lower levels of ROS compared to the bulk tumor cells, 
which gives them an increased resistance to radiotherapy153.  
 
Glioblastoma 
 
Although a relatively rare cancer, glioblastoma is the most common brain cancer with a dismal 
median survival of 12 to 16 months, and only a 4-5% five-year survival rate154. The standard of 
care is surgery, radiation, and treatment with chemotherapeutic temozolomide, but is rarely 
curative155. While glioblastoma has a well-characterized CSC population, the markers to identify 
the CSC population remains somewhat elusive. The presence of CSCs in gliomas has been 
recognized for over a decade, as discovered by the presence of a small population of tumor-
propagating cells expressing markers of neuronal stem cells156. Although CD133+ glioblastoma 
cells have been identified as CSCs, a major limitation remains in that most studies of this cancer 
rely on cell lines and rare cultured primary tumors, almost certainly perturbing the natural CSC 
population157. Key studies utilizing in vitro strategies have identified that forced expression of 
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transcription factors RCOR2, OCT1, SOX2, and SALL2 are sufficient to dedifferentiate non-
tumorigenic glioblastoma cells into CSCs158. The forced expression of these four transcription 
factors restored the tumor-propagating potential of the differentiated cell and gained gene 
expression similar to neural stem cells. The findings also provided tools to identify a more 
meaningful and specific population of CSCs in human glioblastoma tissue samples for future 
studies. 
 Similar to breast CSCs, CD133+ glioblastoma cells were found to have a stronger DDR 
activation in response to radiotherapy compared to the bulk tumor cells159. CSC resistance to 
radiotherapy, despite an initial reduction of bulk tumor, was also shown by increased percentages 
of CD133+ in glioblastomas following radiotherapy, which was reversed with CHK1 and CHK2 
inhibitors in xenograft models159. Temozolomide is the main chemotherapeutic used to treat 
glioblastomas, and it induces DNA damage by alkylating base pairs of the DNA, thus inducing 
apoptosis. Importantly, this type of damage is rapidly repaired by increased expression of 
methylguanine DNA methyltransferase (MGMT). Conflicting findings suggest that some 
glioblastoma CSCs overexpress MGMT, making them more resistant than the bulk tumor, while 
others have lower expression compared to the bulk tumor160,161.  
 
1.4.4 Embryonal carcinoma, a model of curable cancer 
 
Although there are obvious differences between cancer cells and the normal stem cells from which 
they arise, there are often relevant similarities. Many of the mechanisms of CSC chemoresistance 
mentioned above, quiescence, increased checkpoint signaling after damage, and increased MGMT 
expression, are also phenotypes of the stem cells found in their respective tissue of origin. For this 
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reason, the first portion of the introduction was devoted to normal germ cell biology because they 
are the cells from which TGCTs arise. Also as mentioned above, germ cells and other pluripotent 
cells have an increased DDR, making them extremely sensitive to genotoxic chemotherapies. The 
significant risk to fertility among young cancer patients most clearly emphasizes this germ cell 
hypersensitivity162. Based on transcriptional regulators used as diagnostic markers, EC shares 
many of the same pluripotent transcriptional networks as primordial germ cells, or embryonic stem 
cells, which demonstrate hypersensitivity to genotoxic stress compared to most somatic cells35. 
Importantly, EC exists as the CSC component for many mixed TGCTs. As described above, many 
somatic CSCs tend to be resistant to standard of care therapy which may explain why many somatic 
cancers relapse and are not curable, even after a good initial response. However, if TGCT CSCs 
are hypersensitive to the standard of care therapies; then it would help explain their overall high 
cure rate. Demonstrating this would emphasize the potential of CSC-targeted therapies, and place 
importance on gaining a better understanding of the mechanisms behind the in vivo 
chemosensitivity of EC cells.  
 
History of embryonal carcinoma 
 
Leroy Stevens is credited with initiating research of EC. While studying the effects of tobacco on 
mice at Jackson labs in 1953, he discovered that inbred line 129 mice had a high rate of teratoma 
formation163. A year later, he published a study demonstrating that disaggregated cells from a small 
percentage of these teratomas continued to grow when transplanted into syngeneic mice80. Follow-
up experiments by Pierce et al. identified that these teratomas had tissue from all three germ layers 
like all teratomas, but they also harbored a fourth undifferentiated tissue type known as EC164. 
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From this work, these rare tumors were categorized as malignant teratocarcinoma164. A key study 
from the same group in 1964 demonstrated unequivocal evidence that EC is the functional CSC of 
teratocarcinoma43.  
 In those studies, Kleinsmith et al. observed that when teratocarcinoma was transplanted 
intraperitoneally, the mouse would develop ascites with free floating clusters of cells which 
appeared similar to very early embryos. These clusters were aptly called embryoid bodies. Within 
these embryoid bodies, a small percentage of cells were observed to contain EC cells, and when 
single embryoid bodies were transplanted into syngeneic mice, that same small percentage of 
engraftments were successful. To determine if the entire embryoid body was necessary to regrow 
a teratocarcinoma, or if a single EC cell held the unlimited growth and differentiation capacity, 
single cells were engrafted into syngeneic mice. Single cells were carefully isolated from embryoid 
bodies collected from ascites. Using glass capillary tubes, researchers first confirmed the isolation 
of single cells, and then transplanted those cells into 1790 mice, resulting in 43 successful 
engraftments of teratocarcinoma. This set of experiments provided some of the earliest evidence 
that single cells can function as CSCs and demonstrated that EC is functionally the CSC of 
teratocarcinoma43. 
 Continued work with EC laid the groundwork for isolation of embryonic stem cells as well 
as their culture conditions165. Characterization of embryoid bodies morphologically linked EC to 
the inner cell mass (ICM) of early blastocysts outlined in section 2.1166. Finally, in 1981, ICM cells 
were explanted from early stage embryos into teratocarcinoma conditioned media, thus facilitating 
the first embryonic stem cell cultures167. While embryonic stem cells have become a superior 
system for many research applications, EC remains a valuable model of CSCs. Importantly, the 
two cell types share key phenotypes and often respond similarly to a given stimulus. Possibly the 
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most important and well-established similarities are that both cell types express pluripotency 
markers NANOG, OCT4, and SOX2, which are vital transcription factors of pluripotency. 
Substantial differences also exist, such as a unique crosstalk between OCT4 and AKT promotes 
self-renewal in human EC cells but is absent from human ES cells168. Upon in vivo transplantation 
of EC cells form teratocarcinoma; ES cells, on the other hand, only form the teratoma component, 
and fail to maintain their pluripotent stem cell population within the resulting tumor. 
Much more is known about the unique DDR of ES and iPS cells, but there is evidence to 
suggest EC cells share a similar hypersensitivity to DNA damage. One study found that rather than 
a robust P53 mediated transient cell cycle arrest, which can cause chemoresistance in some somatic 
CSCs, EC cells can have a robust P53 mediated senescence response to the same level of 
damage169. Other studies found EC cells have a preferential apoptotic pathway over P21 induced 
cell cycle arrest after damage170. P53 in EC cells appears to be regulated by MDMX and MDM2. 
However, in somatic cancers, activation of P53 by disruption of MDM2-P53 association usually 
leads to P21 induced cell cycle arrest while the same disruption triggers an apoptotic response in 
EC171. All of these data suggest EC cells have a preferential apoptotic response to DNA damage 
similar to other pluripotent cells. Importantly, all of that evidence has been gathered from in vitro 
work using long-term cultured EC cell lines. A lack of a robust TGCT animal model has limited 
the in vivo validation of these findings. However, direct comparison of teratocarcinoma patient 
tumors before and after treatment found that EC cells tend to be eliminated by chemotherapy, 
leaving only the teratoma component, which rarely continues to grow172,173. This depletion 
following treatment is contrary to chemoresistant somatic CSCs, highlighting the functional in 
vivo hypersensitivity of EC under real world conditions.  
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The remaining chapters of this dissertation address important questions about germ cell 
susceptibility to oncogene-induced malignant transformation and provide evidence that malignant 
TGCTs arise from insults during a specific window of embryonic development. I show that EC 
functions as a CSC within our mouse model. The data presented based on this model shows it as 
a relevant system to study malignant TGCTs as well as highly chemosensitive CSCs. This work 
helps us understand why TGCTs respond so well to genotoxic chemotherapies. Furthermore, the 
evidence that an effective therapy against CSCs can dramatically increase survival also serves to 
emphasize that targeting CSCs could be a valuable part of combination therapy. Targeting CSCs 
within chemoresistant somatic cancers may lead to increased cure rates similar to those obtained 
following the introduction of cisplatin and other genotoxic drugs used to treat TGCTs. 
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CHAPTER 2 
CHEMOTHERAPY-INDUCED DEPLETION OF OCT4-POSITIVE CANCER STEM 
CELLS IN A NOVEL MOUSE MODEL OF MALIGNANT TESTICULAR CANCER 
2.1 ABSTRACT 
TGCTs are among the most responsive solid cancers to conventional chemotherapy. To 
elucidate the underlying mechanisms, we developed a mouse testicular germ cell tumor model in 
which germ cell-specific oncogenic Kras activation and tumor suppressor Pten inactivation were 
driven by CRE-mediated recombination. The resulting mice rapidly developed malignant, 
metastatic testicular cancers composed of both teratoma and embryonal carcinoma, the latter of 
which exhibited stem cell characteristics, including expression of the pluripotency factor OCT4. 
Several lines of evidence suggested that germ cell susceptibility to malignant transformation was 
restricted to embryogenesis, with the same oncogenic events triggering apoptosis in adult germ 
cells. Treatment of tumor-bearing mice with genotoxic chemotherapy not only prolonged survival 
and reduced tumor size, but selectively eliminated the OCT4-positive cancer stem cells. We 
conclude that the chemosensitivity of testicular cancers derives from the sensitivity of their cancer 
stem cells to DNA-damaging chemotherapy.  
This chapter represents a manuscript that is currently under review. 
Amy M. Lyndaker*, Timothy M. Pierpont*, Claire M. Anderson, Jamie L. Roden, Alicia Braxton, 
Lina Bagepalli, Nandita Kataria, Hilary Zhaoxu Hu, Jason Garness, Matthew S. Cook, Blanche 
Capel, Donald H. Schlafer, Teresa Southard, and Robert S. Weiss, Chemotherapy-Induced 
Depletion Of Oct4-Positive Cancer Stem Cells In A Novel Mouse Model Of Malignant Testicular 
Cancer. Cell Reports, Submitted 
* These authors contributed equally to the manuscript. 
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I, Timothy M. Pierpont, generated all or partial data for the following figures of Chapter 2: 
 
Figure 2.1 
Figure 2.2 
Figure 2.3 
Figure 2.4 
Figure 2.5 
Figure 2.6 
Figure 2.7 
Figure 2.S1 
Figure 2.S2 
Figure 2.S3 
Figure 2.S6 
Figure 2.S7 
Table 2.S1 
Table 2.S4 
 
 
2.2 STATEMENT OF SIGNIFICANCE 
 
TGCTs are among the most curable solid cancers in humans, yet the mechanisms 
underlying their sensitivity to conventional DNA-damaging chemotherapies remain unclear. Here 
we demonstrate in a novel mouse model of malignant, metastatic testicular cancer that genotoxic 
chemotherapy prolongs survival and reduces testicular germ cell tumor size by preferentially 
depleting the cancer stem cells. 
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2.3 INTRODUCTION 
 
Testicular germ cell tumors (TGCTs) are the most commonly diagnosed cancers in young 
men in the U.S. and Europe and are increasing in incidence174. Intriguingly, testicular cancers are 
among the most responsive cancers to chemotherapy. In the 1970s, prior to the advent of modern 
genotoxic chemotherapy drugs, the five-year survival rate for patients diagnosed with metastatic 
testicular germ cell cancer was only 5%. Remarkably, with conventional chemotherapeutics and 
surgery, 99% of patients with early-stage disease and 74% of patients with late-stage disease now 
live at least 5 years175.As the name implies, TGCTs arise from transformed germ cells, most likely 
prenatal germ cells, such as primordial germ cells or spermatogonial precursors. In the latest 
classification scheme, TGCTs are categorized by whether or not they originate from a precursor 
lesion termed germ cell neoplasia in situ (GCNIS) of the testis176. Seminomas and nonseminomas 
are malignancies that do originate from GCNIS and were referred to as type II TGCTs in earlier 
classifications. These are the most common TGCTs, and they typically occur in adult males and 
frequently metastasize to abdominal lymph nodes, distant lymph nodes, and lung177. TGCTs that 
do not originate from GCNIS include infantile teratomas and yolk sac tumors as well as 
spermatocytic seminomas (previously referred to as type I and type III TGCTs, respectively). To 
date, mouse TGCT models have featured primarily benign teratomas rather than the more common 
malignancies originating from GCNIS. 
Men presenting with TGCTs often have mixed TGCTs comprised of both seminoma and 
nonseminoma components, most notably containing highly malignant embryonal carcinoma (EC) 
tissue. EC cells are totipotent, and are the well-characterized stem cells of TGCTs. Indeed, a single 
EC cell is sufficient to recapitulate an entire tumor43. EC cells share many characteristics with 
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embryonic stem (ES) cells, and are similarly identified by expression of the pluripotency factor 
OCT4178. OCT4 is used clinically as the diagnostic marker for EC and seminoma as well as for 
early pre-invasive GCNIS lesions179. EC cells also express other pluripotency markers, including 
SOX2 and NANOG180,181, and either differentiate, giving rise to teratoma tissue, or remain 
undifferentiated and highly malignant, as they do in metastatic TGCTs such as teratocarcinoma, a 
mixed germ cell tumor composed of EC and teratoma.  
Cancer stem cells (CSCs), also referred to as tumor-initiating cells or tumor-propagating 
cells, are cancer cells with the capacity to self-renew as well as differentiate into the myriad of 
cells found within a malignancy182. Such cell populations have been characterized in several 
cancers, including glioblastomas, breast cancers, and germ cell tumors. Many somatic CSCs have 
been linked with chemoresistance, making them particularly interesting clinically because failure 
to target and eliminate CSCs would leave a patient susceptible to relapse. In contrast to CSCs in 
somatic cancers, EC cells cultured in vitro are sensitive to DNA-damaging chemotherapeutics183. 
We propose that this unique chemosensitivity of germ cell-derived CSCs plays an important role 
in the overall curability of testicular cancer and highlights the potential benefit of developing 
combination therapies that successfully target CSCs in cancers that are refractory to current 
treatments. 
The molecular basis for the chemosensitivity of TGCTs remains elusive. One explanation 
for why somatic cancers are resistant to genotoxic chemotherapy is that they accumulate mutations 
in their DDR pathways, most notoriously in the p53 gene92. p53, MDC1, 53BP1, and other DDR 
signals, like the early double-strand break marker H2AX, are often constitutively active in early-
stage somatic cancers90,93. This DDR activation can act as a tumorigenesis barrier by slowing or 
halting cell cycle progression in the presence of oncogene-induced DNA damage, but may also 
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create selective pressure to mutate the genes involved in maintaining that barrier, thus facilitating 
continued tumorigenesis despite genomic instability90,92,93. Once DDR genes have been mutated, 
cells no longer respond appropriately to DNA damage, including damage induced by 
chemotherapy drugs like cisplatin, ultimately allowing avoidance of DNA damage-induced 
apoptotic signals. Unlike solid tumors of somatic origin, human TGCTs do not exhibit constitutive 
DDR activation during early tumorigenesis93. This lack of DDR signaling in TGCTs may alleviate 
the selective pressure to mutate DDR genes, such as Atm and p53, which are mutated at unusually 
low frequency in TGCTs compared to somatically derived solid tumors.92,93.  
Previous studies of malignant TGCTs have focused primarily on analysis of cultured tumor 
cells and histological sections of human tumors, since genetically engineered mouse models of 
TGCT have been limited to those that develop well-differentiated teratomas with little EC and low 
rates of metastasis, thus being representative of the less-common pediatric TGCTs. These mouse 
teratoma models include a conditional knockout of the Pten tumor suppressor targeted to 
primordial germ cells83 as well as 129-Dnd1Ter/Ter mice184, which are homozygous for a mutation 
in the Dead end gene85. Interestingly, these mouse models of testicular teratoma are limited to the 
129 strain background; the Dnd1Ter/Ter mutation leads to BAX-mediated germ cell apoptosis rather 
than tumorigenesis on other strain backgrounds185.  
Susceptibility genes have been identified for mouse testicular teratomas, including the Steel 
locus, which encodes Kit ligand186, as well as additional genes on Chromosome 19 (MOLF-Chr. 
19 strain84); and the X chromosome187. Genome-wide association studies have identified similar 
susceptibility factors in human TGCTs, including PTEN and KITLG188. Inactivating Pten 
mutations in humans specifically mark the transition from TGCT precursor lesions to invasive 
germ cell tumors66. The emerging links between TGCT susceptibility and Kitlg and Pten 
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alterations are particularly interesting, since both are functionally related to the RAS signaling 
pathways that normally promote cellular proliferation. Activating mutations in the Kras (K-Ras) 
oncogene are very common in a variety of cancers. The most common chromosomal aberration in 
human TGCTs is isochromosome 12p188, an additional copy of a region from the small arm of 
Chromosome 12 which contains the Kras gene (Kras2) as well as several stem cell-related genes 
(Nanog, Stella, Cyclin D2, Cd9, Gdf3, Edr1).  
In order to develop a genetically engineered TGCT mouse model representative of 
malignant TGCTs in men, we targeted both Kras activation and Pten tumor suppressor inactivation 
to pre-meiotic germ cells, which led to rapid development of metastatic mixed testicular germ cell 
tumors in young male mice. These malignancies contained substantial populations of pluripotent 
EC cells with tumor-propagating activity, and these cancer stem cells were selectively depleted 
following chemotherapy, defining a key determinant of the remarkable chemosensitivity of 
TGCTs.   
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2.4 RESULTS 
 
Generation of germ cell-specific Pten and Kras (gPAK) mutant mice. In order to study the 
remarkable responsiveness of TGCTs to DNA-damaging chemotherapeutics, we developed the 
first genetically engineered mouse model of malignant, metastatic TGCT by conditionally 
activating the Kras oncogene and inactivating the Pten tumor suppressor gene specifically in germ 
cells. This was accomplished using mice carrying a G12D activating mutation in the first exon of 
the endogenous Kras gene, preceded by a conditional LoxP-Stop-LoxP cassette (LSL-KrasG12D;189), 
as well as a conditional allele of Pten (Ptenflox/flox) in which the critical exon 5 is flanked by LoxP 
sites190. Recombination between adjacent LoxP sites, which enables KrasG12D expression and 
inactivates Pten, was mediated by the CRE recombinase under control of a portion of the Stra8 
(stimulated by retinoic acid 8) promoter (Stra8-Cre191), which is active primarily in mitotic 
spermatogonia in early postnatal life and continuing throughout adulthood. Double mutant 
experimental animals, which we refer to as gPAK mice for germ cell-specific Pten and Kras 
mutant mice, harbored one conditional and one null allele of Pten Ptenflox/-), one copy of the 
conditional LSL-KrasG12D allele (Kras+/LSL), and the Stra8-Cre transgene (Stra8-CreTg) on a mixed 
strain background. Single and double mutant mice were obtained at expected frequencies, 
indicating that these manipulations did not cause embryonic lethality or severe developmental 
abnormalities. 
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Figure 2.1. Combined Pten inactivation and oncogenic KrasG12D activation in early germ cells 
results in rapid testicular tumorigenesis. A. Kaplan-Meier tumor-free survival curve depicting 
that 75% of Stra8-CreTg Ptenflox/- Kras+/LSL (Pten/Kras double mutant, or gPAK) mice and 17% of 
Stra8-CreTg Ptenflox/- Kras+/+ (Pten single mutant) mice developed palpable testicular cancers by 
approximately 4 weeks of age. No tumors developed in Stra8-CreTg Pten+/flox Kras+/LSL (Kras 
single mutant) or control mice (including Cre-negative as well as Stra8-CreTg Pten+/flox Kras+/+ 
animals). Tumor-free survival was significantly reduced in gPAK mice relative to controls (log 
rank test; p=1.56 x10-6), but not in Pten single mutants despite low incidence tumor formation (log 
rank test; p=0.0713). B-D. High magnification images of differentiated tissues from all three germ 
layers within gPAK TGCTs indicative of teratomatous components, including: respiratory 
epithelium (B; endoderm), neural cells (C; ectoderm), and skeletal muscle (D; mesoderm). E. Low 
magnification image of EC within a teratocarcinoma. F. Higher magnification of EC from panel 
E. G. EC present in a lumbar lymph node metastasis. Scale bars represent 100 µm. 
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Simultaneous Stra8-Cre-driven Kras activation and Pten inactivation result in testicular germ cell 
tumorigenesis. While Kras activation or Pten inactivation individually rarely resulted in TGCT 
formation, combined Kras activation and Pten inactivation in gPAK mice led to rapid germ cell 
tumorigenesis, with 75% of gPAK mice succumbing to large bilateral or unilateral TGCTs with a 
median tumor-free survival of 24.5 days (Fig. 2.1A).  Although rare spontaneous TGCTs can 
develop in mice, pairwise log-rank tests between gPAK mice and control animals revealed a highly 
significant reduction in tumor-free survival (p=1.56x10-6), with no control mice developing tumors 
within the same time period.  
TGCTs in these mice were characterized histologically as teratocarcinomas, which are 
mixed germ cell tumors (nonseminoma) containing teratomatous components, including tissues 
derived from all three germ layers, such as respiratory epithelium (endoderm; Fig. 2.1B), neural 
rosettes (ectoderm; Fig. 2.1C), and skeletal muscle (mesoderm; Fig. 2.1D), as well as highly 
malignant EC tissue (Fig. 2.1E,F). Metastases that histopathologically resembled the primary 
neoplasms were detected in at least 37% of TGCT-bearing gPAK mice at various sites, including 
spleen, liver, pancreas, and abdominal lymph nodes (Fig. 2.1G).   
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Figure 2.2. gPAK testicular germ cell tumors contain OCT4-positive cell clusters that express 
pluripotency markers but not SOX17 or H2AX. Immunohistochemical staining for stem cell 
and proliferation markers of gPAK tumors (A-F) and 129-Dnd1Ter/Ter tumors (G). A. OCT4-
positive cells in gPAK TGCTs are also positive for NANOG, SSEA1, and SOX2. B. OCT4-
positive regions of gPAK TGCTs are distinct from those expressing SOX17 and include 
proliferating, Ki67-positive cells. C. Low magnification view of OCT4-positive cell distribution 
in a primary gPAK TGCT. D. OCT4-positive EC within a proximal lymph node metastasis (see 
Fig. 1G for H&E image of a serial section from this tumor). E,F. Serial-sectioned TGCTs from 10-
day old (E) or 14-day old (F) gPAK mice indicating that the DNA damage marker H2AX is not 
present in early-stage gPAK TGCT cells expressing OCT4. Meiotic germ cells surrounding the 
neoplasm exhibit expected levels of H2AX. G. Lack of OCT4 expression in 129-DndTer/Ter 
teratomas, which express SOX2 and SOX17. Scale bars represent 200 µm. 
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Supplemental Figure 2.S1. OCT4 positive cells are retained in multiple sequential 
transplantations. H&E staining (left column) revealed similar morphology of primary gPAK 
TGCT (top row) compared to tumors arising from transplanted tumor cells (bottom two rows). 
OCT4 positive embryonal carcinoma is also present in the primary TGCT and retained in the 
transplanted tumors (right column).  
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Supplemental Table 2.S1. Serial transplantation of primary tumors into 
immunocompromised mice. Tumors were disaggregated to single cell suspension, and 500k 
cells per flank were transplanted into immunocompromised mice. Cells for the primary 
transplant came from disaggregated primary gPAK TGCTs; cells for the secondary transplant 
came from a primary transplant tumor; cells for the tertiary transplant came from a secondary 
transplant tumor. N/D: Not done. 
 
 
  
Sites 
Injected
Tumors 
formed
Sites 
Injected
Tumors 
formed
Sites 
Injected
Tumors 
formed
primary tumor 1 3 3 2 2 2 2
primary tumor 2 2 2 2 2 2 0
primary tumor 3 2 2 2 2 N/D N/D
primary tumor 4 2 2 N/D N/D N/D N/D
primary tumor 5 2 2 N/D N/D N/D N/D
Primary 
Transplant
Secondary 
Transplant
Tertiary 
Transplant
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Supplemental Figure 2.S2. OCT4-GFP expressing gPAK cells have higher tumor 
propagating potential compared to OCT4-GFP negative gPAK cells. Gross images of gPAK 
TGCTs from mice harboring OCT4-GFP transgene (A), as well as serial sections stained for H&E, 
OCT4, and GFP from the same tumor (B). Tumors were disaggregated into single cells and sorted 
using FACS into OCT4-GFP positive and negative cell populations in (C). Both populations were 
injected into the flanks of immune compromised mice. OCT4-GFP positive cells were able to 
propagate the tumor when 20,000 cells were injected, while 40,000 – 100,000 negative cells were 
not sufficient for tumor propagation. 
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gPAK TGCTs express OCT4 and other pluripotency markers. The OCT4 (POU5F1) transcription 
factor is a key regulator of pluripotency, and is one of the four Yamanaka factors that together can 
induce pluripotency in differentiated cells. OCT4 expression is used in human patients as a 
diagnostic marker for EC as well as for TGCT precursor lesions (ITGCNU/CIS)179. The presence 
of EC is the main histological feature that distinguishes teratocarcinoma from benign teratoma. To 
assess OCT4 expression in gPAK TGCTs, we performed OCT4 immunohistochemistry on serial 
sections from early- and late-stage gPAK teratocarcinomas and metastases, as well as on benign 
129-Dnd1Ter/Ter teratomas for comparative purposes. All gPAK tumors from adult mice contained 
prominent clusters of OCT4-positive cells distributed in a multifocal pattern throughout the 
primary tumors (Fig. 2.2A-C), as did 50% of metastases (Fig. 2.2D; proximal lymph node 
metastasis). Distinct clusters of OCT4-positive cells were also prominent in early-stage gPAK 
tumors at P10 (Fig. 2.2E) and P14 (Fig. 2.2F). In contrast, 3 out of 3 129-Dnd1Ter/Ter teratoma 
samples were OCT4-negative (Fig. 2.2G). In addition to the use of OCT4 in human TGCT 
diagnostics, an array of stem cell markers has been established for distinguishing between subtypes 
of TGCTs. For example, NANOG is a specific marker of EC and seminoma as well as the 
precursor lesion GCNIS, and is not expressed in teratomas181, and SOX2 is expressed in EC but 
not in GCNIS or seminoma180. SOX17 is present in GCNIS, seminoma, and teratoma, but not in 
EC180,192. Similar to what has been reported for human specimens192, 129-Dnd1Ter/Ter teratomas did 
contain cells expressing SOX2 and SOX17, whereas EC clusters within gPAK teratocarcinomas 
were positive for the stem cell markers OCT4, NANOG, SSEA1, and SOX2, but were devoid of 
SOX17 (Fig. 2.2A,B,G). gPAK TGCTs were also highly proliferative, as indicated by Ki67 
staining (Fig. 2.2B). Thus, gPAK TGCTs express the same stem cell-associated markers as human 
malignant TGCTs. To determine whether gPAK EC were CSCs, we first tested for tumor 
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propagation by transplantation into secondary recipient mice. Whereas teratomas fail to form 
secondary tumors upon transplantation193, gPAK TGCTs could readily be transplanted into 
secondary recipient mice and serially propagated (Table 2.S1), and the resulting tumors contained 
OCT4+ EC cells (Fig. 2.S1). These results suggested that EC, the malignant component of 
teratocarcinoma that is lacking in teratoma, had tumor-propagating activity, in agreement with 
previous studies43. To confirm this, we bred an OCT4-GFP transgene into the gPAK model, 
isolated OCT4+ and OCT4- cells from the resulting tumors, and tested tumor-propagating activity 
by transplantation (Fig. 2.S2). The OCT4+ population formed teratocarcinoma in secondary hosts 
whereas OCT4- cells did not, confirming that the OCT4+ EC cells have tumor-propagating activity 
and function as CSCs.  
Most pre-invasive somatic cancers express markers of DNA damage response (DDR) 
activation, including H2AX, but human TGCTs interestingly lack such activation90,92,93. It has 
been proposed that a lack of constitutive DDR activation in TGCTs may reduce selective pressure 
to mutate key DDR genes that enforce the anti-cancer barrier, explaining why TGCTs have a much 
lower frequency of mutations in DDR genes like p53 compared to somatic cancers. To test whether 
gPAK mouse TGCTs similarly share this property, we assessed the presence of H2AX, one of 
the earliest DDR signals at DNA damage sites, in gPAK TGCTs collected at P10 and P14. Similar 
to what has been reported for early-stage human TGCTs92, we found that gPAK TGCTs were 
devoid of H2AX-positive cells. H2AX expression was instead confined to the meiotic cells of 
the seminiferous epithelium, which are known to mount a developmentally appropriate DDR 
associated with meiotic events (Fig. 2.2E,F). These results provide further parallels between the 
gPAK TGCT model and human disease, establishing the utility of gPAK mice for investigating 
the link between DDR activation status and chemosensitivity in these uniquely treatable cancers. 
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gPAK TGCTs originate during embryonic development. The rapid development of TGCTs in 
gPAK mice prompted us to examine the precise timing of tumor initiation in this model. Stra8 is 
a developmentally regulated gene that is expressed in early germ cells just prior to their entry into 
the meiotic program194. In mice, Stra8 is typically expressed in spermatogonia beginning at P3. 
The Stra8-Cre transgene, used here to generate gPAK mice, contains a fragment of the Stra8 
promoter that is reported to be expressed in spermatogonial stem cells191. While Stra8-Cre has 
been shown to be expressed at P3 in the pre-meiotic spermatogonial cells191, we observed 
substantial tumors, sometimes occupying the majority of the testis, in 3 out of 4 gPAK mice at 
P10, 1 out of 1 gPAK mouse at P6, and 3 out of 7 gPAK mice at P3, as well as 2 out of 5 Pten 
single mutant mice at P3, suggesting that the neoplasms originate prior to P3 (Fig. 2.3A). 
Furthermore, all gPAK mice that developed TGCTs did so by 33 days. Thus, in order to determine 
the developmental timing of Pten/Kras manipulation in our model, we used a CRE-responsive 
fluorescent reporter (B6;129S6-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J) and assessed the precise 
timing of Stra8-Cre activity. While Stra8-Cre was broadly expressed in spermatogonia beginning 
at P3 (Fig. 2.3B), a few small clusters of tdTomato-positive cells (indicative of Stra8-Cre 
expression) were identifiable within the seminiferous tubules beginning at E12.5 and observed in 
6 out of 6 embryos (Fig. 2.3B). No tdTomato-positive cells were detected prior to E12.5.  From 
E13.5 to E18.5 the number and approximate size of the clusters remained unchanged.  Beginning 
at P0, additional individual cells throughout the testes became tdTomato-positive and the clusters 
also expanded, resulting in staining throughout the testes by P3. Similar results were observed with 
a LacZ reporter (Fig. 2.S3). The presence of these infrequent clusters of Cre-expressing cells in 
the embryonic testis, together with our observations of only one or two tumor initiation sites per 
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testis in gPAK mice, is consistent with the notion that germ cell tumorigenesis in the gPAK model 
arises from rare, early Stra8-Cre expression in only a few germ cells during embryogenesis.  
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Figure 2.3. gPAK testicular tumors initiate during embryonic development. A. H&E staining 
and OCT4 IHC on serial sections from gPAK TGCTs at postnatal day 3 and 6 indicating substantial 
tumor growth at these early developmental stages. B. tdTomato expression (top) indicating Stra8-
Cre activity in embryonic germ cells at E12.5 and E18.5 with an absence of expression at E11.5. 
Postnatal expression at P0 with increasingly widespread expression shown at P3. Counter stained 
with DAPI or tissue shown in brightfield (bottom). Scale bars represent 100 µm (A) or 75 µm (B). 
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Supplemental Figure 2.S3. Lineage tracing analysis of Stra8-Cre expression in testes using a 
lacZ reporter. X-gal staining of fixed tissue sections highlights cells that have experienced Stra8-
Cre-mediated excision, at postnatal day 6 (A), 3 (B), 0 (C), and embryonic day E16.5 (D) in 
animals of the indicated genotypes, counterstained with nuclear fast red. B-G, middle and right 
images. High and low magnification images of disaggregated whole-mount testes show X-gal 
staining in isolated clusters of cells, indicating Stra8-Cre activity in embryonic germ cells. 
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Testicular germ cells exhibit a restricted developmental window of susceptibility to oncogenic 
transformation. Since Stra8-Cre expression occurs early in embryonic testis, and gPAK tumor 
formation appears to initiate from rare CRE-expressing embryonic germ cells, we were interested 
in understanding the impact of oncogenic events occurring at higher frequency with the onset of 
broader CRE expression at P3. Germ cell proliferation and germ cell numbers were therefore 
quantified in post-natal gPAK mice without apparent neoplasms. We first assessed the cellularity 
of P3 gPAK testes (Fig. 2.4A) and performed IHC staining for mouse VASA homolog 
(MVH/Ddx4; Fig. 2.4B), which marks early germ cells195. No significant differences in germ cell 
numbers were detected at P3 in any of the tumor-free single or double mutants (Fig. 2.4C). There 
was, however, increased cellularity in the seminiferous epithelium of gPAK testes relative to 
controls at P10 and P17 (Fig. 2.4D). To measure proliferating germ cells, we performed IHC 
staining for the proliferation marker phospho-histone H3 (pH3). Tumor-free gPAK testes had 
significantly increased numbers of pH3-positive cells at P10 relative to controls (p=0.045), but not 
at P3 (Fig. 2.4E, F). Interestingly proliferation returned to normal levels by P17 in tumor-free 
gPAK testes and was followed by dysplastic changes in the testis as early as P30 and P40, 
accompanied by significantly increased germ cell death (p<0.005) (Fig. 2.5A, B).  
 By P180 the seminiferous tubules of tumor-free gPAK mice exhibited prominent 
degenerative changes including vacuolization, pyknotic nuclei, and multinucleate spermatid giant 
cells as well as increased numbers of TUNEL-positive apoptotic cells (Fig. 2.5C-E; p=0.002). 25% 
of gPAK mice never developed tumors, and these tumor-free adult gPAK mice had decreased testis 
size and significantly decreased numbers of epididymal sperm (p<0.005 and p<0.001, respectively; 
Fig. 2.5F,G). Pten single mutants showed increased vacuolization and degenerative changes at 
P180 (Fig. 2.5C), as well as increased germ cell apoptosis (Fig. 2.5D,E; p=0.01) and significantly 
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reduced sperm counts (Fig. 2.5G; p<0.001). That some gPAK mice experience testicular 
degeneration rather than tumorigenesis suggests that germ cell transformation in this model is a 
relatively rare cellular event, likely occurring during a restricted development window during 
embryogenesis when male germ cells are susceptible to malignant transformation. Subsequent 
widespread oncogenic events in post-natal germ cells (P3 and beyond) initially promote germ cell 
hyperproliferation in the postnatal testis but ultimately lead to germ cell death and impaired 
fertility rather than malignant transformation and tumorigenesis. 
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Figure 2.4. gPAK testes exhibit increased cellularity and phospho-histone H3-positive cells 
in early postnatal life. A-C. Comparable numbers of germ cells are detected in gPAK and control 
testes at P3 as shown in representative H&E staining (A) and IHC for the germ cell marker MVH 
(B; quantified in C). D-E. H&E (D) and phospho-histone H3 IHC staining (E) of P10 and P17 
control and gPAK testes indicating increased cellularity in the seminiferous tubules of gPAK mice 
compared to controls at both time points. Increased numbers of mitotic cells, shown by phospho-
histone H3 staining, were detected in gPAK mice relative to controls at P10 (mean +/- SD; 
Student’s T-Test; p=0.045), but not P17. Scale bars represent 100 µm. 
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Figure 2.5. Combined Pten inactivation and Kras activation in postnatal germ cells is 
associated with dysplastic histological changes in the testis, reduced testis size, and reduced 
sperm counts in non-tumor-bearing mice. A. H&E staining of P30 and P40 gPAK testes 
indicates increased germ cell abnormalities compared to controls. B. gPAK testes exhibit 
significantly more tubules with apoptotic germ cells as measured by TUNEL staining (mean +/- 
SD; n=3, Student’s T-test; p<0.005) compared to controls (n=3). C-E. 6-month old gPAK mice 
exhibit significant dysplastic changes in the testis and loss of sperm production. C,D. H&E and 
TUNEL staining 6-month old male mice indicating significant vacuolization, increased presence 
of multinucleate spermatid giant cells and pyknotic nuclei, decreased tubule diameter, and 
increased apoptosis in gPAK and Pten mutants (quantified in E; mean +/- SD; Student’s T-Test; 
p=0.002; p=0.01 respectively). F,G. Graphical representations of testis weights (F) and sperm 
counts (G) from six-month old mice (mean +/- SEM; *p<0.005, Student’s T-test; **p<0.001, 
Tukey-Kramer HSD test). Scale bars represent 200 µm. 
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gPAK tumor cells are predominantly diploid and harbor recurrent DNA copy number aberrations.  
Aneuploidy is a distinguishing characteristic of most cancers, with karyotypes ranging from gain 
or loss of single chromosomes to whole-genome duplication, most often with additional 
chromosome rearrangements as well as copy number aberrations. Interestingly, teratomas have 
been reported to have normal diploid chromosome numbers50. To test this, and also to determine 
whether an absence of oncogene-induced DNA damage might underlie the lack of DNA damage 
response activation seen in human TGCTs93, we performed metaphase chromosome analysis of 
gPAK teratocarcinoma cells as well as cells from benign 129-Dnd1Ter/Ter mouse teratomas. As 
shown in Fig. 2.S4, cells from both tumor types were primarily diploid, with a mean metaphase 
chromosome number between 38 and 42, indicating that the increased malignancy of germ cell-
derived tumors in the gPAK mouse model versus the 129-Dnd1Ter/Ter model is not associated with 
gross chromosomal instability. These results are consistent with previous studies of cultured mouse 
teratocarcinoma cells, which found that the tumorigenic cells had near-diploid chromosome 
numbers196. Thus, if tumorigenesis is associated with oncogene-induced DNA damage in this 
model, the damage must be comprised of smaller-scale aberrations rather than gross changes in 
chromosome number or structure.   
To further assess oncogene-induced genomic alterations in gPAK tumors, we analyzed 
copy number aberrations via array comparative genome hybridization (aCGH). As depicted in Fig. 
2.S5A and summarized in Table 2.S2, gPAK tumors harbored recurrent gains and losses of copy 
number across the six tumors analyzed, including events on Chromosomes 1, 7, 9, 12, 14, 17, and 
X. A subset of the regions recurrently altered in gPAK tumors were also altered in 129-Dnd1Ter/Ter 
tumors (Table 2.S2, right), such as loss of Chr. 7qA3 (Fig. 2.S5B), which was confirmed in both 
tumor types by qPCR (Fig. 2.S5C). 129-Dnd1Ter/Ter teratomas additionally harbored recurrent copy 
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number changes on Chromosomes 4, 6, 11, and 20 that were not identified in gPAK tumors (Table 
2.S3). Analysis of the altered gPAK chromosomal regions via Panther and Enrichr gene list 
analysis tools revealed enrichment for G-protein-coupled receptors (p=3.45x10-21) and receptors 
(p=1.79x10-11) as well as for genes regulated by particular transcription factors, most notably 
SOX2 (33/188 genes, p=4.97x10-18; Table 2.S4). SOX2 is highly expressed in gPAK neoplasms, 
likely reflecting the cell of origin and consistent with the idea that regions of the genome containing 
highly expressed gene clusters are prone to replication-associated chromosome breakage197. 
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Supplemental Figure 2.S4. Cells isolated from gPAK teratocarcinomas and 129-Dnd1Ter/Ter 
teratomas contain predominantly diploid cells. A,C. Representative Giemsa-stained diploid 
metaphase chromosome spreads from early-passage cultured gPAK (A) and 129-Dnd1Ter/Ter (C) 
tumor cells. B,D. Chromosome counts from gPAK (B) or 129-Dnd1Ter/Ter (D) tumors, with results 
for three independent cultured tumors per genotype shown (N>100 per genotype). The majority of 
cells contained a diploid genome, while a small percentage of cells exhibited aneuploidy. 
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Supplemental Table 2.S2. Minimal common regions (MCRs) of high frequency DNA copy 
number aberration in gPAK tumors as identified via array CGH. Summary of minimal 
common regions (greater than 100kb) of copy number aberrations found in at least 50% of gPAK 
tumors, including chromosome band, genomic coordinates, frequency, and included genes. 
Regions also altered in 129-Dnd1Ter/Ter tumors are indicated at the right.  
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Supplemental Figure 2.S5. Array comparative genome hybridization (aCGH) analysis of 
gPAK and 129-Dnd1Ter/Ter tumors reveals recurrent copy number aberrations (CNAs). A. 
Karyotype depiction of copy number aberrations in six gPAK teratocarcinomas compared to 
control spleen tissue via aCGH using Roche Nimblegen mouse 3x720k whole-genome tiling 
arrays, with amplifications shown as green lines to the right of each chromosome and deletions 
shown as red lines to the left. B. Segment of mouse Chromosome 7 (7qA3) with copy number 
aberrations in both gPAK and 129-Dnd1Ter/Ter tumors. C. qPCR validation of Chr. 7qA3 deletion 
in both gPAK and 129-Dnd1Ter/Ter tumors.   
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Supplemental Table 2.S3. Minimal common regions (MCRs) of high frequency DNA copy 
number aberration in 129-Dnd1Ter/Ter tumors as identified via array CGH. Summary of 
minimal common regions (greater than 100kb) of copy number aberrations found in at least 50% 
of 129-Dnd1Ter/Ter tumors, including chromosome band, genomic coordinates, frequency, and 
included genes. 
 
 
Chromosome Band Start End Length (bases) Frequency Gain(+)/loss(-) Protein-coding genes Non-coding RNAs
4 A5 42,379,999 42,659,999 280,000 0.5 +
Gm21586, Gm10597, Gm3883, Gm2163, Gm13298, Gm10592, Gm10591, 
Gm2564, Ccl27b, Il11ra2
4 A5 41,859,999 42,099,999 240,000 0.5 +
Gm21966, Gm21541, Gm29878, Gm20938, Gm21093, Gm10597, Gm21968, 
Gm393
4 E1 143,099,999 144,419,999 1,320,000 0.5 + Prdm2, Pdpn, Lrrc38, Pramel1, Pramef8, Oog4 Gm22039 snoRNA, Gm26313 misc RNA
4 112,219,999 113,939,999 1,720,000 0.5 +
Gm13043, Gm13040, BC080695, Gm13057, Gm13083, Gm13088, Gm13089, 
Gm13078, Gm13023, Gm13084, Gm13103, Pramef6, Gm13109, Gm13101, 
Pramef17, Pramel4, Gm13102, Oog3, Oog2, C87977, Pramel5, Gm13128, 
Gm13119, Gm13125, Pramef12, 1700012P22Rik
6 F3 129,939,999 130,579,999 640,000 0.5 + Klra6, Klra4, Klra8, Klra9, Klra7, Klra10, Klra13, Klra3, Klra1 Gm22555 snRNA, Gm24676 snRNA, Gm22621 
snRNA, Gm24712 snRNA, Gm23552 snRNA 
Gm24072 snRNA
7 E1 92,099,999 94,299,999 2,200,000 0.5 + Dlg2, Ccdc90b, Ankrd42, Pcf11, Rab30, 4632434l11Rik, Prcp, Gm9934, Gm15501 Gm22734 miRNA, Gm26944 lincRNA, Gm26981 
lincRNA, Gm26862 lincRNA, Gm25860 snoRNA
7 C 67,819,999 68,139,999 320,000 0.5 + Igf1r
7 B5-C 60,099,999 60,979,999 880,000 0.5 + Gm7367
7 B1 32,419,999 34,259,999 1,840,000 0.5 +
Scgb1b29, Scgb2b15, Scgb2b17, Scgb1b19, Scgb2b20, Scgb1b21, Scgb2b24, 
Scgb1b24 , Scgb2b26, Scgb2b27, Scgb1b27, Scgb1b30, Wtip, Uba2, Pdcd2l, 
Gpi1, 4931406P16Rik, Gm12758, Gm6096
Gm24766 miRNA, Gm25817 miRNA, Gm12763 
lincRNA, Gm26443 miRNA, Gm26762 lincRNA
11 B4 71,019,999 71,139,999 120,000 0.5 + Nlrp1a 6330403K07Rik lincRNA
12 F2 115,939,999 116,779,999 840,000 0.5 + Ighv1, Zfp386,Vipr2, Gm20658, Wdr60, Gm11027, Esyt2, Ncapg2, Ptpm2
Gm23732 snRNA, Gm23190 miRNA, Gm25112 
snRNA, Gm24354 snRNA
12 F2 114,979,999 115,539,999 560,000 0.5 +
Ighv1-47, Ighv8-4, Ighv1-49, Ighv8-5, Ighv1-50, Ighv1-52, Ighv1-53, Ighv8-6, Ighv1-
54, Ighv1-55, Ighv1-56, Ighv8-8, Ighv1-58, Ighv1-59, Ighv1-61, Ighv1-62-1, Ighv1-62-
2, Ighv1-62-3, Ighv8-9, Ighv1-63, Ighv1-64
AC164609.1 miRNA
12 E 104,979,999 105,179,999 200,000 0.5 + Glrx5, Tcl1b2, Tcl1b5 Scarma13 snoRNA
20 A1.1 3,019,999 4,899,999 1,880,000 0.5 -
Gm21950, Gm21364, Gm14346, Gm14345, Gm14351, Gm3701, Gm3706, 
Gm14347, Gm10921, Gm10922, Gm3750
20 F5 166,419,999 166,644,267 224,268 0.5 - Ofd1, Trappc2, Rab9, Tceanc, Egfl6 Gm15226 lincRNA
MCR coordinates
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Supplemental Table 2.S4. gPAK MCRs are enriched for genes regulated by SOX2. Summary 
table from Enrichr analysis indicating genes from gPAK MCRs enriched for particular 
transcription factors, most notably SOX2. 
 
 
 
  
Transcription factor P-value # genes from gPAK MCRs (total regulated genes) Genes
SOX2 4.97E-18 33/188 (1878)
GM3750;4930555G01RIK;GM10666;VMN1R125;VMN1R128;VMN1R124;VMN1R143;VMN1R142;VMN1R139; 
VMN1R130;VMN1R129;VMN1R183;VMN1R171;VMN1R174;VMN1R175;VMN1R173;VMN1R176;GM14345; 
GM14347;GM14346;GM16451;VMN1R68;VMN1R69;VMN2R30;VMN2R35;VMN2R39;V1RD19;VMN2R66;DYNLT1F; 
DYNLT1A; DYNLT1C;DYNLT1B;PEBP4
CBEPB 7.65E-17 41/188 (3275)
NLRP5;VMN1R126;VMN1R125;VMN1R128;VMN1R127;VMN1R124;VMN1R143;VMN1R142;VMN1R139;VMN1R130;
VMN1R129;VMN1R168;VMN1R181;VMN1R183;VMN1R171;VMN1R174;VMN1R175;VMN1R172;VMN1R173; 
VMN1R177;CYP2A22;TTC23;PEBP4;LRRC28;4930555G01RIK;CYP2G1;GM10666;GM16451;VMN2R30;VMN2R31; 
VMN2R33;VMN2R35;VMN2R36;VMN2R37;VMN2R39;VMN2R49;VMN2R47;VMN2R45;VMN2R46;VMN2R66;NRXN3
ETV4 1.63E-13 28/188 (1773)
CYP2G1;VMN1R128;GM4172;VMN1R183;VMN1R171;VMN1R175;VMN1R176;GM2897;GM3696;GM10406; 
VMN1R68;VMN2R30;VMN2R31;VMN2R32;VMN2R33;VMN2R35;VMN2R36;VMN2R39;VMN2R40;VMN2R49; 
VMN2R47;VMN2R48;VMN2R45;VMN2R46;GM8453;VMN2R66;NRXN3;PEBP4
POU2F1 4.95E-12 26/188 (1735)
GM14632;LRRC28;GM3750;VMN1R126;GM2897;GM14351;GM14345;GM14347;GM14346;GM3696;GM10406; 
VMN1R68;VMN1R69;TTC23;VMN1R70;VMN2R30;VMN2R35;VMN2R37;VMN2R49;VMN2R47;VMN2R45;V1RD19; 
DYNLT1F;DYNLT1C;DYNLT1B;GM10487
POU2F2 4.32E-08 21/188 (1754)
GM14632;LRRC28;GM2897;GM14351;GM14345;GM14347;GM14346;GM3696;GM10406;VMN1R69;TTC23;VMN1R70;
VMN2R30;VMN2R37;VMN2R47;V1RD19;DYNLT1F;DYNLT1A;DYNLT1C;DYNLT1B;GM10487
SREBF1 8.34E-07 19/188 (1735)
GM10666;VMN1R126;VMN1R125;VMN1R127;VMN1R124;GM4172;VMN1R143;VMN1R142;VMN1R139;VMN1R130;
GM5891;VMN1R68;VMN2R44;V1RD19;GM8453;DYNLT1F;DYNLT1C;DYNLT1B;SYNM
SRF 5.28E-06 18/188 (1782)
KCTD6;GM3750;VMN1R128;GM4172;VMN1R143;GM14351;GM14345;GM14347;GM14346;VMN1R68;VMN1R69; 
VMN2R31;VMN2R33;VMN2R52;TULP4;GM8453;D830030K20RIK;VMN2R66
TBP 4.82E-06 25/188 (3182)
VMN1R125;VMN1R128;VMN1R124;GM4172;VMN1R143;VMN1R139;VMN1R130;VMN1R171;VMN1R174; 
VMN1R172;GM5891;D830030K20RIK;DYNLT1F;DYNLT1C;DYNLT1B;PEBP4;4930555G01RIK;SYTL3;VMN2R30; 
VMN2R31;VMN2R33;VMN2R35;VMN2R47;VMN2R46;VMN2R66
NFYB 1.65E-05 17/188 (1748)
GM10666;VMN1R126;VMN1R125;VMN1R128;VMN1R127;VMN1R124;GM4172;VMN1R143;VMN1R142;VMN1R139;
VMN1R130;GM5891;GM16451;VMN1R68;VMN2R44;V1RD19;GM8453
CPEB1 1.65E-05 17/188 (1748)
GM10666;VMN1R126;VMN1R125;VMN1R128;VMN1R127;VMN1R124;GM4172;VMN1R143;VMN1R142;VMN1R139;
VMN1R130;GM5891;GM16451;VMN1R68;VMN2R44;V1RD19;GM8453
RBPJ 5.74E-05 16/188 (1735)
GM10666;VMN1R125;VMN1R128;VMN1R127;GM4172;VMN1R143;VMN1R142;VMN1R139;VMN1R130;VMN1R129;
VMN1R181;VMN1R172;GM16451;VMN1R70;V1RD19;GM8453
NFYA 6.27E-05 16/188 (1748)
GM10666;VMN1R126;VMN1R125;VMN1R128;VMN1R127;VMN1R124;GM4172;VMN1R143;VMN1R142;VMN1R139;
VMN1R130;GM5891;VMN1R68;VMN2R44;V1RD19;GM8453
FOS 1.73E-04 15/188 (1708)
ACOX2;VMN1R129;GM16451;VMN2R30;VMN2R31;VMN2R33;VMN2R36;VMN2R40;VMN2R49;VMN2R47; 
VMN2R48;VMN2R46;DYNLT1B;FAM107A;SYNM
CBEPA 2.44E-04 15/188 (1764)
GM14632;CYP2G1;GM10666;GM4172;VMN1R129;VMN1R174;VMN1R175;VMN1R176;VMN1R177;GM14347; 
GM16451;VMN1R68;VMN2R30;VMN2R46;GM10487
USF1 3.03E-04 12/188 (1219)
SYTL3;VMN2R30;VMN2R31;VMN2R32;VMN2R33;VMN2R37;VMN2R39;VMN2R44;VMN2R49;VMN2R47;VMN2R45; 
VMN2R46
IRF2 5.74E-04 14/188 (1706)
NLRP5;GM10666;GM4172;PXK;VMN1R129;VMN1R181;GM16451;VMN2R32;VMN2R40;V1RD19;DYNLT1F;DYNLT1C;
DYNLT1B;NRXN3
GATA1 6.77E-04 14/188 (1735)
ABHD6;GM10666;VMN1R126;VMN1R127;GM4172;VMN1R142;VMN1R168;VMN1R171;VMN1R174;VMN1R175; 
CYP2A22;V1RD19;NRXN3;PEBP4
NR2F1 1.04E-03 10/188 (1021) GM16451;SYTL3;GM10666;CYP2A5;VMN1R126;VMN1R128;VMN1R143;VMN1R130;VMN1R129;DYNLT1A
RORB 1.03E-03 10/188 (1020) GM16451;SYTL3;GM10666;CYP2A5;VMN1R126;VMN1R128;VMN1R143;VMN1R130;VMN1R129;DYNLT1A
SOX10 2.56E-03 6/188 (451) ACOX2;GM14351;GM14345;GM14347;GM14346;GM3750
STAT5B 2.01E-03 13/188 (1729)
GM3750;NLRP5;VMN1R181;VMN1R174;GM14351;GM14345;GM14346;VMN2R37;OIT1;DYNLT1A;NRXN3;PEBP4; 
FAM107A
JUND 2.40E-03 13/188 (1764)
FLNB;VMN1R176;VMN1R68;VMN1R69;VMN2R32;VMN2R36;VMN2R37;VMN2R40;VMN2R48;VMN2R45;DYNLT1F; 
DYNLT1A;DYNLT1B
SPI1 4.56E-03 12/188 (1680) ABHD6;GM3750;SYTL3;VMN1R143;VMN1R130;CYP2A22;GM2897;GM3696;GM10406;VMN2R32;VMN2R49;PEBP4
HMGA1 1.60E-02 11/188 (1748) KCTD6;CYP2G1;VMN1R175;VMN1R176;VMN1R69;VMN2R30;VMN2R37;VMN2R49;VMN2R47;VMN2R48;VMN2R66
4.66E-02 3/188 (264) TTC23;LRRC28;FAM107A
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gPAK TGCTs are sensitive to chemotherapy. TGCTs in humans are exquisitely sensitive to the 
DNA-damaging chemotherapeutic cisplatin, which is used routinely as a frontline drug in 
combination with bleomycin and etoposide. To determine whether gPAK TGCTs were also 
sensitive to cisplatin, gPAK mice were treated intraperitoneally with either two 6 mg/kg cisplatin 
doses, or a full course of bleomycin/etoposide/cisplatin (BEP) at doses comparable to those used 
in humans. Cisplatin-treated gPAK mice lived significantly longer than untreated gPAK mice 
(p=0.0192), with a median survival of 36 days for untreated mice and 49 days for cisplatin-treated 
mice (Fig. 2.6A). Two cisplatin doses were not sufficient to eradicate the tumors, and both treated 
and untreated mice ultimately reached humane endpoint criteria; however, primary tumor volume 
at endpoint was significantly lower in cisplatin-treated gPAK mice than in untreated animals 
(p=0.004; Fig. 2.6B). gPAK mice were even more responsive to BEP, with several mice surviving 
to an arbitrary 100 day end point (median survival of 87.5 days; p<0.001) and primary tumor 
volume significantly reduced (p=0.002).  Thus, gPAK murine TGCTs, similar to their human 
counterparts, can be effectively treated with chemotherapy, even in the absence of the surgical 
interventions that typically accompany chemotherapy in humans. 
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Figure 2.6. Genotoxic chemotherapeutic treatment of gPAK mice prolongs survival and 
selectively depletes OCT4-positive cells. A. Kaplan-Meier survival curve indicating prolonged 
survival of gPAK mice following two intraperitoneal doses of 6 mg/kg cisplatin, or a 4 week 
regiment of bleomycin, etoposide, and cisplatin (BEP). The median survival of cisplatin-treated 
mice was 13 days greater than in untreated mice (N=10 and 8, respectively; log-rank test; p<0.02) 
while the median survival of BEP-treated mice was 58 days longer than in untreated mice (N=5; 
log-rank test; p<0.0005). B. Primary tumor volume measured at endpoint and was significantly 
reduced in cisplatin-treated gPAK mice (N=9; mean +/- SEM; Student’s T-Test; p=0.007) and 
BEP-treated mice (N=4; mean +/- SEM; Student’s T-Test; p<0.002). C. Representative images of 
OCT4 IHC on primary TGCTs from untreated, cisplatin-treated, and BEP-treated gPAK mice (see 
Fig. S6 for representative SOX17 images). Scale bars represent 200 µm. D. Quantification of 
OCT4-positive (Student’s T-Test; p=0.02 (cisplatin); p<0.002 (BEP)) and E. SOX17-positive 
(Student’s T-Test; p=0.098 (cisplatin); p=0.67 (BEP)) cells in untreated, cisplatin-treated, and 
BEP-treated gPAK TGCTs, counted using Image-J. 
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Supplemental Figure 2.S6. SOX17-positive cells are not depleted in gPAK tumors following 
genotoxic treatment. Representative images of SOX17 IHC from cisplatin-treated, BEP-treated 
and untreated gPAK tumors from the same experiment shown in Fig. 6 (see quantification in Fig. 
6E). 
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gPAK CSCs are significantly depleted following genotoxic chemotherapy. To directly test how EC 
cells respond to chemotherapy in vivo, we quantified OCT4-expressing cells in gPAK tumors 
collected at endpoint from mice treated with BEP or cisplatin alone. Strikingly, the percentage of 
OCT4-positive cells was significantly reduced in the gPAK mice treated with either cisplatin alone 
or BEP (Fig. 2.6C,D; p=0.02 and p=0.01 respectively). This result suggested that not only were 
the gPAK tumors sensitive to chemotherapy, but the OCT4-positive EC cells were more sensitive 
than the bulk tumor cells. To further test whether the loss of OCT4-positive cells was specific and 
not a consequence of loss of bulk tumor cells, we also assessed the staining pattern for SOX17, 
which is present in a subset of non-EC cells of the tumor. The percentage of SOX17-positive cells 
within gPAK TGCTs was not decreased in response to BEP or cisplatin treatment, in stark contrast 
to what we observed for the OCT4+ EC cells (Fig. 2.S6 and Fig. 2.6E). We conclude that TGCT 
chemosensitivity is specifically linked to the elevated sensitivity of EC cells to genotoxic 
chemotherapy. Since EC cells are the cancer stem cells of TGCTs, this selective sensitivity may 
explain why chemotherapy in humans is more effective against TGCTs than other somatically-
derived solid cancers. 
 In order to understand the acute responses to chemotherapy in gPAK TGCTs, tumor-
bearing gPAK mice were treated with a single dose of 6 mg/kg cisplatin and euthanized at 12 or 
48 hours post-treatment. At 12 hours post-treatment, the number of apoptotic cells was increased 
relative to untreated gPAK TGCTs, particularly within OCT4-positive clusters (Fig. 2.7A,B). 
Apoptosis was reduced by 48 hours, by which time nearly all OCT4-positive cell clusters exhibited 
altered morphology and reduced cell number compared to untreated TGCTs (Fig. 2.7C). 
Importantly, this indicates that the OCT4-positive EC cells in gPAK TGCTs are sensitive to 
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cisplatin-induced DNA damage, which leads to rapid initiation of apoptosis and reduction in the 
number of CSCs. 
Following chemotherapeutic treatment, it is widely accepted that surviving CSCs that are 
refractory to treatment can cause tumor recurrence. To determine whether the reduced amount of 
EC in gPAK tumors post-treatment correlated with reduced tumor-propagating activity, we 
compared tumor formation following transplantation of tumor cells from treated or untreated 
gPAK mice. Subcutaneous injection of 10,000 cells from untreated gPAK TGCTs was sufficient 
to produce tumors at 75% of injection sites (n=16; Fig. 2.7D and Table 2.S5). By contrast, 25,000 
gPAK tumor cells transplanted 48 hours post-cisplatin treatment failed to result in tumor formation 
in recipient mice (n=20). Tumor-propagating activity was not completely eradicated by cisplatin 
treatment, as transplantation of 1 million or 100,000 cells from treated gPAK tumors was sufficient 
for tumor formation, though with much longer latency than observed for untreated tumor cells 
(p<0.005). Limiting dilution calculations based on these data estimated a frequency of viable CSCs 
of 1 in 9167 tumor cells from untreated gPAK TGCTs, which likely underestimates the true 
frequency of the CSCs due to EC cell death during tumor disaggregation (Table 2.S5). Notably, 
cisplatin-treated gPAK TGCTs contained only 1 CSC in 252,332 tumor cells, signifying a 28-fold 
reduction in CSC frequency following treatment. Since a single intact EC cell is sufficient to 
induce tumorigenesis43, these results support the notion that the high chemosensitivity of TGCT 
CSCs underlies the remarkable curability of TGCTs. 
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Figure 2.7. Cisplatin treatment of gPAK TGCTs induces apoptosis of OCT4-positive cells 
and reduces tumorigenicity of transplanted tumor cells.  A-C. TGCT-bearing gPAK mice were 
euthanized either without treatment (A), or 12 (B) or 48 (C) hours following a single intraperitoneal 
dose of 6 mg/kg of cisplatin. Serial sections of fixed tumors were stained with H&E, OCT4 (to 
identify EC) or TUNEL (to detect apoptosis) indicating a wave of apoptosis among EC cells at 12 
hours post treatment. Portions of gPAK primary TGCTs, from either untreated mice, or mice 
euthanized 48 hours post-treatment, were digested to a single cell suspension, and the indicated 
number of single cells allografted into the flanks of NOD.CB17-Prkdcscid/J mice via subcutaneous 
injection (see Table 2.S5 for a breakdown of tumor incidence and primary tumor source). D. 
Kaplan-Meier tumor-free survival curve showing 25,000 post-treated cells (n=20) did not form 
tumors at injection sites while 75% of sites injected with 10,000 untreated cells (n=16) formed 
tumors that reached approximately 200 mm 3-5 weeks post-transplant (log-rank test p<0.005). 
Scale bars represent 400 µm. 
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Supplemental Table 2.S5. Tumor incidence and latency following injection of untreated or 
cisplatin-treated gPAK TGCT cells into recipient mice. Mice harboring primary gPAK TGCTs 
were either treated with 1 dose of 6 mg/kg cisplatin 48 hours before necropsy, or left untreated. 
gPAK primary tumors collected at necropsy were digested to a single cell suspension, and the 
indicated number of cells allografted into the flanks of NOD.CB17-Prkdcscid/J mice via 
subcutaneous injection. *indicates cells were resuspended in DMEM containing 10% FBS, LIF, 
and ROCKi (others were resuspended in DMEM alone) for ~45 minutes prior to transplantation. 
ROCK inhibition helps prevent apoptosis in EC cells induced by contact loss during 
disaggregation, and likely increased the number of viable CSCs transplanted, resulting in the 
observed 100% tumor initiation with 10,000 non-cisplatin treated TGCT cells pretreated with 
ROCKi. 
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Primary 
TGCT
Number of 
cells injected
Injection 
sites
Tumors 
formed
Mean 
Latency
A 1 x 10
6
3 3 19
B 1 x 10
6
2 2 13
C 1 x 10
6
2 2 13
D 5 x 10
5
2 2 18
E 5 x 10
5
2 2 17
C 1 x 10
5
2 2 19.5
F 2.5 x 10
4
1 1 36
G 2.5 x 10
4
2 1 20
C 1 x 10
4
4 4 24
F 1 x 10
4
4 0 -
F * 1 x 10
4
2 2 32
G 1 x 10
4
4 4 30.75
G * 1 x 10
4
2 2 22
C 1 x 10
3
4 1 33
F 1 x 10
3
2 0 -
G 1 x 10
3
2 2 30
H 1 x 10
6
2 2 36
H 1 x 10
5
2 2 45
I 2.5 x 10
4
6 0 -
J 2.5 x 10
4
6 0 -
K 2.5 x 10
4
6 0 -
K * 2.5 x 10
4
2 0 -
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Supplemental Figure 2.S7. Schematic representation of the temporal susceptibility of germ 
cells to malignant transformation.  Oncogenic events in germ cells during embryogenesis can 
cause malignant transformation and tumorigenesis, while postnatal germ cells initially 
hyperproliferate but then undergo apoptosis in response to the same oncogenic events. See text 
for details. 
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2.5 DISCUSSION 
 
 In this study, we developed a novel mouse model of malignant TGCT that, like human 
TGCTs, exhibits high sensitivity to the chemotherapeutic cisplatin. Using this model, we have 
revealed that the unusual chemosensitivity of TGCTs is associated with an inherent sensitivity of 
EC cells, the CSCs of TGCT, to elimination by conventional genotoxic chemotherapeutic agents. 
This is in contrast to most CSCs, which are refractory to treatment and often contribute to tumor 
recurrence and disease relapse following initial chemotherapeutic treatment182. This establishes a 
powerful system for testing the molecular mechanism underlying the chemosensitivity of these 
unique cancer stem cells, which we hypothesize is a direct consequence of germ cells having 
distinct responses to DNA damage compared to other cell types. Since there are several known 
determinants of cisplatin sensitivity, including DNA repair factors, studies of their roles in EC 
cells may reveal strategies for sensitizing other types of cancers with chemoresistant CSCs. The 
apparent proliferative state of gPAK CSCs may also contribute to their chemosensitivity, as 
quiescence may help CSCs in other tumors survive genotoxic therapies. 
 We observed tumors in gPAK mice as early as postnatal day 3, indicating that the tumors 
most likely do not arise from postnatal initiation events but rather from rare transformation of late 
embryonic germ cells. Consistent with this, we were able to detect Stra8-Cre-mediated 
recombination in a few small clusters of testicular germ cells at E12.5 and subsequently observed 
only 1-2 neoplasms per testis. It remains unknown whether the embryonic Cre expression observed 
in this model reflects the normal activity of the Stra8 promoter or is unique to the Stra8-Cre 
transgene. However, it is worth noting that male germ cells show endogenous Stra8 mRNA 
expression at E13.5198 and a small subset of male germ cells express meiotic markers at E14.5199, 
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suggesting that Stra8 expression can occur naturally during embryonic germ cell development. 
Regardless, the data suggest that gPAK TGCT initiation occurs in early/mid-embryonic germ cells, 
a time point between PGC arrival at the gonad and the onset of G0 cell cycle arrest200. Notably, 
teratoma formation in DndTer mice is associated with a failure of embryonic germ cells to undergo 
proper mitotic arrest, suggesting that G0 arrest and downregulation of pluripotency gene 
expression at E12.5 to E15.5 may mark the end of the period during which germ cells are 
particularly susceptible to malignant transformation201. Interestingly, Kras and Pten targeting in 
postnatal germ cells initially triggered widespread overproliferation but ultimately lead to cell 
death and germ cell depletion. This suggests the existence of mechanisms that protect against 
oncogenic events in adult germ cells but fail to prevent sustained hyperproliferation at certain 
stages of embryogenesis. Interestingly, loss of the pro-apoptotic gene Bax causes testis 
hypercellularity soon after birth, followed by massive cell death at P25, suggesting the existence 
of mechanisms to eliminate excess germ cells from adult testes202. 
The gPAK model is representative of human testicular cancer, given that most human 
TGCTs have malignant components, and our work is consistent with the possibility that human 
TGCTs may arise from embryonic oncogenic insults. It is particularly striking that there seems to 
be a specific developmental window within which early germ cells are susceptible to oncogenic 
transformation (Fig. 2.S7). This mimics the case in humans, where epidemiologic data indicate 
that TGCT risk in men is associated with in utero environmental exposures185. Despite presumed 
initiation during embryogenesis, human TGCTs originating from GCNIS do not typically present 
until adulthood, likely due to hormone production beginning at puberty.  
It is unclear why Kras activation or Pten inactivation alone is insufficient to cause germ 
cell tumorigenesis in the majority of cases. It has been reported previously that loss of Pten driven 
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by Stra8-Cre does not induce TGCTs or affect fertility203, although in our studies we did see 
infrequent TGCTs as well as germ cell loss with Pten deletion alone. No TGCTs were observed in 
mice with Stra8-Cre-driven Kras activation alone even after one year. Why is Ras activation 
insufficient for oncogenic transformation in germ cells, but sufficient in other tissues? It is well 
documented that some mouse tissues are more susceptible to Ras-induced transformation than 
others. Mice expressing activated oncogenic Kras in somatic tissues, either constitutively or 
spontaneously, primarily develop lung cancers as well as oral, gastric, and skin papillomas and 
thymic lymphomas, whereas neoplastic lesions were not detected during the same time period in 
pancreas, liver, or small intestine204,205. Similarly, Pten inactivation leads to tumorigenesis in lung, 
skin, prostate epithelium, mammary epithelium, and T-cells, but rarely in the GI tract206. While 
Pten loss and Kras activation lead to some of the same downstream effects, substantial evidence 
indicates that these can be potent collaborating events during tumorigenesis. In mouse models of 
ovarian cancer, concomitant Pten and Kras alterations result in development of serous papillary 
adenocarcinomas207. Furthermore, Pten loss accelerates Kras-induced pancreatic cancer 
development208, and promotes metastatic progression of Kras-activated melanomas209. Thus, Pten 
loss and Kras activation are functionally non-equivalent, despite their overlapping impact on key 
signaling pathways, and in the context of germ cells strongly synergize to promote TGCT 
formation.  
 The contrasting effects of Pten and Kras alterations in germ cells may be particularly 
relevant to their modulation of the germline stem cell pool. Pten inactivation in oocytes has been 
shown to promote premature activation of the entire primordial follicle pool, causing an initial 
surge of follicle maturation that leads to premature ovarian failure due to loss of the oocyte 
reserve210. Ras activation in cultured spermatogonial stem cells (SSCs), on the other hand, 
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promotes self-renewal rather than proliferation and differentiation211. Interestingly, excessive Ras-
mediated self-renewal in these cultured SSCs led to development of germ cell tumors upon 
transplantation into murine testes. It is possible that the combined Pten inactivation and Kras 
activation in our model promotes premature cell division of SSC precursors concomitant with 
activation of excessive self-renewal signals, leading to development of germ cell-derived tumors 
containing OCT4-positive malignant stem cells (EC cells). Supporting this idea is the fact that 
Pten null mouse pluripotent stem cells cultured in vitro develop into aggressive, tumorigenic EC 
cells through increased survival and self-renewal caused by loss of Nanog repression212.  
 Many open questions remain regarding TGCT biology, most notably related to the 
fundamental differences in the cell of origin between germ cell and somatically-derived cancers 
and the different molecular mechanisms governing their responses to oncogenic transformation. 
In stark contrast to most somatically-derived cancers, early-stage testicular germ cell cancers in 
our gPAK mice and in humans92 lack the DNA damage response marker H2AX. This fundamental 
difference in response to oncogene-induced DNA damage may be due to differential DDR wiring 
of germ cells versus somatic cells, with germ cells primed to apoptose in response to damage rather 
than risk faulty DNA repair. Alternatively, it is possible that the pre-meiotic germ cells have a 
dampened DDR in order to allow full DDR activation following meiotic DSB induction, which is 
absolutely necessary for completion of meiosis and production of functional sperm. It remains to 
be seen whether germ cells in fact incur as much DNA damage in response to oncogenic 
proliferation as do somatic cells, which would also impact DDR activation status. Interestingly, 
ES cells contain greater numbers of dormant origins than more differentiated cells213, and it is 
conceivable that embryonic germ cells could use this or related mechanisms to protect against 
replication stress that normally accompanies oncogene-induced hyperproliferation. Whether the 
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DDR is differentially regulated depending on germ cell developmental stage also remains to be 
determined. For instance, whereas embryonic germ cells do not appear to mount a DDR against 
oncogenic events, the germ cell apoptosis and infertility associated with oncogenic events in adult 
gPAK germ cells could reflect a DDR triggered by replication stress associated with the 
widespread hyperproliferation observed at P10. Identification of what makes TGCT CSCs so 
sensitive to DNA-damaging chemotherapeutics may provide avenues for the development of more 
effective therapies for other cancers by targeting their more deadly, chemoresistant CSCs. 
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2.6 METHODS 
 
Mouse strains and husbandry. Stra8-Cre transgenic mice191 were obtained on the FVB background 
and then backcrossed to 129SvEv for greater than 10 generations. LSL-KrasG12D mice189 were 
backcrossed to 129SvEv for greater than 10 generations. Ptenflox/flox 214 were obtained on a mixed 
B6/129/FVB strain background. 129-Dnd1Ter/Ter mice85 were maintained in the Capel laboratory at 
Duke University Medical Center. Pten+/flox mice were crossed to Stra8-Cre transgenic animals to 
generate Stra8-Cre-positive Pten+/- mice. Ptenfloxlflox mice were crossed with LoxP-Stop-LoxP-
KrasG12D mice (referred to here as KrasLSL) to generate Ptenflox/flox Kras+/LSL mice. In order to 
generate the experimental gPAK animals (Stra8-Cre+ Ptenflox/- Kras+/LSL), Stra8-Cre+ Pten+/- mice 
were crossed to Ptenflox/flox Kras+/LSL mice. To generate gPAK mice with Oct4-Gfp, Stra8-Cre+ 
Pten+/- mice were crossed with B6;CBA-Tg(Pou5f1-EGFP)2Mnn/J215 and the resulting Oct4-Gfp, 
Stra8-Cre+ Pten+/- were bred with Ptenflox/flox Kras+/LSL. In order to generate LoxP-Stop-LoxP-LacZ 
or LoxP-Stop-LoxP-tdTomato reporter mice, Stra8-Cre+ mice were bred with B6;129S4-
Gt(ROSA)26Sortm1Sor/J (Soriano 1999), or B6;129S6-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J216, 
respectively. Oct4-gfp, LSL-Lacz, and tdTomato mice were all used on a mixed 129SvEv/C57BL/6 
background.  All animals used in this study were handled in accordance with federal and 
institutional guidelines, under a protocol approved by the Cornell University Institutional Animal 
Care and Use Committee (IACUC). Mice with tumors were monitored daily and sacrificed upon 
reaching humane endpoint criteria. 
 
Histology and immunohistochemistry. Tissues were fixed overnight at 4C in Bouin’s fixative or 
at room temperature in fresh 4% paraformaldehyde (Sigma-Aldrich) in PBS, embedded in wax, 
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and sectioned at 5 µm. Immunohistochemical staining for OCT4 (Abcam ab19857, 1:1000) and 
H2AX (Millipore 05-636, 1:200) was done using heat-mediated antigen retrieval in EDTA, pH 
8.0, while SOX17 (Neuromics GT15024, 1:500), SOX2 (Seven Hills WRAB-1236, 1:500), MVH 
(Abcam ab13840, 1:200), Ki67 (Vector VP-K452, 1:20), SSEA1 (Hybridoma MC-480, 1:10), and 
Nanog (Abcam ab80892, 1:400) staining was done using heat-mediated antigen retrieval in citrate 
buffer, pH 6.0. After rehydration and antigen retrieval, primary antibody was incubated overnight 
followed by biotinylated secondary antibody and then streptavidin HRP conjugate (Invitrogen 
Histostain SP) incubations at room temperature. Finally, positive cells were visualized with DAB 
(Invitrogen) and counterstained with 1:1 hematoxylin (Fisher CS401-1D) solution before 
dehydration. SOX17 immunohistochemistry was performed with anti-goat biotinylated secondary 
antibody (Vector BA-5000, 1:200). TUNEL assays were performed using the Apoptag kit 
(Millipore) as per the manufacturer's instructions.  
 
Metaphase chromosome analysis. gPAK or 129-Dnd1Ter/Ter testicular tumor cells were isolated 
from three primary tumors per genotype and disaggregated by treatment with 2 mg/mL 
Collagenase A (Roche) in serum-free DMEM with penicillin, streptomycin, and gentamycin at 
37C for approximately 1 hour prior to culturing on gelatin-coated plates in DMEM (Cellgro) 
supplemented with 10% fetal bovine serum (Gibco), non-essential amino acids (Cellgro), 
penicillin/streptomycin (Cellgro), and L-glutamine (Cellgro). Metaphase chromosome analysis 
was performed on low-passage cells by incubating with 10 µg/mL colcemid (Invitrogen) at 37C 
for 1.5 hours, after which trypsinized cells were incubated in 0.075 M KCl hypotonization buffer 
at 37C for 12 minutes and washed with prior to fixation in fresh ice-cold 3:1 methanol:acetic acid 
fixative. Cells were spotted on charged microscope slides (Fisher Scientific), dried, and stained for 
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5 minutes in fresh Giemsa stain (Harleco, Original Azure Blend) diluted 1:50 in Gurr buffer (BDH 
Laboratory Supplies) before imaging by standard light microscopy.   
 
Array comparative genome hybridization (CGH). DNA was isolated from gPAK or 129-
Dnd1Ter/Ter testicular tumors by dounce homogenization, phenol/chloroform extraction, and 
ethanol precipitation. Six tumors per mouse genotype were assessed relative to one spleen DNA 
control sample using NimbleGen Mouse CGH 3x720k Whole Genome Tiling Arrays (Roche) and 
processed at the Cornell University Biotechnology Resource Center’s Genomics Facility. Partial 
karyotype depiction of gPAK copy number aberration data (Fig. 2.S5A) was generated using 
waviCGH217 via median normalization, mean pre-processing, DNA copy segmentation, 
probability calling, and minimal common region permutations. Small CNAs and sex chromosomes 
not depicted. Recurrent copy number changes listed in Tables S2 and S3 were found in at least 3 
out of 6 tumors of the indicated genotype and had minimal common regions (MCRs) of 100kb or 
greater. Quantitative PCR validation of 7qA3 deletion in gPAK and 129-Dnd1Ter/Ter tumors was 
performed using SYBR green detection, alpha-actin endogenous control, and primers 7delF1 
(TGGTGAGTGGTCTTCGTTTC) and 7delR1 (ACAGCTGAGGAACAGGATTG). Control 
DNA was extracted from grossly normal spleen from the same animals. For lists of genes contained 
within MCRs, gene identity as protein-coding versus non-coding RNA was determined initially in 
waviCGH and reassessed using the Mouse Genome Informatics database 
(www.informatics.jax.org), with pseudogenes removed (Tables S2 and S3). The set of genes found 
in gPAK MCRs was analyzed using Panther to assess enrichment for particular gene 
functions218,219 and Enrichr to determine enrichment for genes regulated by particular transcription 
factors220, as listed in Supplemental Table S4.  
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Lineage tracing with LacZ and tdTomato reporters. For LacZ staining, embryos were collected at 
E13.5, 16.5, or E18.5, and young pups euthanized at postnatal day zero (P0), P3, or P6. Testes 
were extracted, the tunica removed, and tubules manually spread before fixation in fresh 4% 
paraformaldehyde in PBS with 2 mM MgCl for 30 minutes on ice. Testes were then incubated in 
staining solution (10mM PO4 buffer pH7.4, 150 mM NaCl, 1 mM MgCl2, 3 mM K4[Fe(CN)6], and 
3 mM K3[Fe(CN)6], 1 mg/ml of X-gal) at 37C for either 6 hours, or overnight for E16.5 and 
younger. Samples were paraffin-embedded, sectioned at 5 µm, and counterstained with nuclear 
fast red (Acros Organics). 
 For tdTomato visualization, testes from B6;129S4-Gt(ROSA)26Sortm1Sor/J Stra8-cre+ mice 
were collected at E11.5, E12.5, E18.5, postnatal day zero (P0), or P3. Testes were dissected out 
from animals at E18.5 or older, while E12.5 and E11.5 samples were fixed as whole embryos. All 
tissues were fixed in fresh 4% paraformaldehyde for 30 minutes on ice. Tissues were then washed 
in cold 1xPBS before being flash frozen in O.C.T. compound and cryosectioned at 20µm 
thicknesses. Sections were mounted on slides and covered with DAPI containing mounting 
medium before being analyzed for the presence of tdTomato positive cells localized to the gonads. 
 
Sperm counts. Mature spermatozoa were isolated from the caudal epididymis as described 
previously221. Briefly, both epididymides from each mouse were minced and incubated in 1 mL 
warm PBS for 30 minutes, after which the sperm suspension was fixed in 10% neutral-buffered 
formalin and counted using a hemacytometer. Data are shown as the mean ± SEM, and values 
were analyzed statistically using a Tukey-Kramer test. 
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Chemotherapy treatments. Cisplatin (Sigma P-4394) was dissolved in 0.9% NaCl to a 
concentration of 1 mg/mL and stored at room temperature for up to 1 month. For survival analysis, 
gPAK mice were randomly selected for intraperitoneal injection of 6 mg/kg cisplatin at weaning 
and again one week later, or at the same time points with 0.9% NaCl for control injections. Mice 
were monitored until reaching one of three humane endpoints: quiet and unresponsive, have an 
external TGCT ulcerate or reach greater than 2.0cm3, or were severely bloated, piloerect, and 
showed signs of dehydration. gPAK mice that did not develop TGCTs were excluded from the 
analysis. OCT4-positive cells were identified via immunohistochemical staining and quantified 
using ImageJ. For assessing acute responses to cisplatin, mice with detectable TGCTs were given 
one dose of 6 mg/kg of cisplatin intraperitoneally and euthanized 12 or 48 hours post-injection. 
All samples were fixed in fresh 4% paraformaldehyde for 24 hours.  
 For BEP treated mice, the same endpoints and cisplatin source was used, but treatment 
included bleomycin (Selleckchem) dissolved in 0.9% NaCl, and etoposide (Selleckchem) 
dissolved in 5% DMSO, with all drug prepared to 0.5mg/mL. BEP mice were treated for four 
weeks on a repeating 7 day cycle during which they received 1.8mg/kg cisplatin and 5.0mg/kg 
etoposide on days 1-5, and 1.8mg/kg bleomycin on day 2, of all four cycles. Some doses were 
temporarily postponed, before resumption of the treatment cycle, if drug toxicity was observed 
based on weight loss or severe dehydration, and wet food was given. 
 
gPAK TGCT transplantation. gPAK testicular tumors were isolated from gPAK mice 48 hours 
post-cisplatin-treatment (or from untreated controls) and disaggregated with 2 mg/mL Collagenase 
A (Roche) in serum-free DMEM with penicillin, streptomycin, and gentamycin at 37C for 
approximately 1 hour, shaking. Cells were then passed through a 4 µM filter to remove large 
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clumps, pelleted at 1.5 x g for 5 minutes, then resuspended in DMEM or DMEM + 10% FBS, + 
1x LIF, + 10 µM ROCK inhibitor prior to injection. Approximately 30 minutes prior to injection, 
the desired number of cells were suspended in 100 µl PBS. Just prior to injection, 100 µL of cells 
were mixed with 100 µL matrigel (BP Biosciences) in a 1 mL syringe and injected subcutaneously 
into the flanks of NOD.CB17-Prkdcscid/J mice. Mice were monitored regularly for tumor 
development and sacrificed upon reaching humane endpoint criteria. Tumor-free survival data was 
analyzed in a Kaplan-Meier plot. Limiting dilution calculations done according to222. 
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CHAPTER 3 
CULTURED EMBRYONAL CARCINOMA CELLS RETAIN CANCER STEM CELL 
PROPERTIES AND EXHIBIT HYPERSENSITIVITY TO CISPLATIN 
3.1 ABSTRACT 
The cellular mechanisms underlying the chemosensitivity of testicular germ cell tumors (TGCTs) 
remains an elusive but important area of research. Although cisplatin and other genotoxic 
chemotherapies are used to treat a variety of late-stage cancers, TGCTs are the only solid cancer 
that achieves 71% five-year survival rates. Many cell culture models of human and murine 
malignant TGCTs exist, yet most of these cell lines have been maintained in vitro for decades, 
likely subjecting the cells to artificial selective pressures that may affect results. In this study, we 
isolated two new embryonal carcinoma (EC) cell lines from a novel mouse model in which TGCTs 
arise due to germ cell specific Pten inactivation alone, or in combination with oncogenic Kras 
activation. EC cells are established as TGCT cancer stem cells (CSCs) that retain the ability to 
self-renew as well as differentiate into teratoma tissues. Both EC cell lines retained their 
pluripotent phenotype and tumor-propagating abilities without notable changes. Following 
exposure to differentiation reagents thioridazine or retinoic acid, both EC lines exhibited loss of 
pluripotency and tumor propagation potential. We hypothesized that EC cells possess a unique 
DDR that underlies their heightened chemosensitive to genotoxic drugs like cisplatin. To test this, 
we treated EC cells and their differentiated counterparts with cisplatin. Both EC cell lines showed 
significantly reduced survival compared to their respective differentiated derivatives. Studying 
these EC cells along with differentiated controls will provide new insight into the basis of TGCT 
chemosensitivity in humans. 
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3.2 INTRODUCTION 
 
Testicular germ cell tumors (TGCTs) are the most common malignancy among men 15 to 40 years 
of age and are increasing in prevalence in developed countries39. Before the advent of genotoxic 
chemotherapies, advanced stages of this disease had a dismal 5% five-year survival rate71. Now 
treated with a combination of bleomycin, etoposide, and cisplatin (BEP), the same advanced stage 
of TGCT has a 71% survival, and near 100% when detected early71. This success story of treatment 
advancement for TGCTs is historic. However, it remains unknown why these tumors respond so 
well to genotoxic chemotherapies while so many somatic cancers remain resistant. A better 
understanding of the mechanisms underlying the therapeutic response to genotoxic 
chemotherapies may help better treat resistant cancers. 
 TGCTs can be divided into two broad categories based on whether they derive from a 
known precursor lesion, germ cell neoplasia in situ (GCNIS), or not29,30. TGCTs derived from 
GCNIS comprise the majority of all germ cell tumors and tend to be highly malignant yet carry a 
good prognosis with BEP therapy and surgery223. Embryonal carcinoma (EC) is a totipotent cancer 
cell type found in approximately 80% of all non-seminomas. Commonly, EC cells present together 
with more differentiated tumor tissue lineages from all three germ layers known as a teratoma. 
Malignancies with both teratoma and EC components are defined as teratocarcinoma. 
EC cells are the established CSC of teratocarcinoma, which is supported by data shown in 
Chapter 2 (Fig. 2.S1, 2.S2). CSCs are cancer cells with the ability to divide indefinitely while both 
self-renewing and undergoing alterations to produce the heterogeneity of a given malignancy134. 
CSCs have been identified in a variety of cancers, most notably leukemia, breast, brain, and germ 
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cell cancers43,135,148,156. Importantly, in somatic cancers, CSCs tend to be more resistant to 
chemotherapy224. This is of great clinical significance in that, despite initial positive response to 
treatment, viable CSCs can evade chemotherapy. In such cases, the malignancy is able to regrow 
and ultimately be incurable. Alternatively, targeting the CSC in combination with conventional 
treatments could increase survival among resistant cancers. Because EC is the CSC of 
teratocarcinoma, for which there is a highly efficacious treatment, understanding EC response to 
treatment is a key component of understanding the high cure rate among TGCTs. 
Some evidence exists to suggest that EC cells have a robust DDR responsible for their 
hypersensitivity to genotoxic drugs. Two major apoptotic responses unique to pluripotent cells, 
which are lost upon differentiation, are primed BAX and a reduced or non-existent G1/S 
checkpoint125,127,129. Embryonic stem (ES) cells and induced pluripotent (iPS) cells are both known 
to share this hypersensitivity to DNA damage125,126. BAX oligomerization and localization to the 
mitochondrial membrane is a necessary step in apoptosis, but BAX is cytosolic and only activated 
upon sufficient DNA damage in the vast majority of cells. In ES and iPS cells, BAX was found 
already activated and stored at the golgi where it more rapidly localized to the mitochondria to 
induce apoptosis upon DNA damage127. This phenotype was lost upon differentiation127. 
Additionally, ES cells lack, or have a reduced, G1 checkpoint in mice and human-derived cells 
respectively. 
In 1953, Leroy Stevens initated research in EC when he discovered that inbred line 129 
mice had a high rate of teratoma formation163. Follow-up experiments showed that some of these 
germ cell tumors harbored EC cells and could be propagated indefinitely80,164. From this work, 
these rare tumors were categorized as malignant teratocarcinoma164. Kleinsmith et al. observed 
that when teratocarcinoma was transplanted intraperitoneally, the mouse would develop ascites 
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with free floating clusters of cells which appeared similar to very early embryos called embryoid 
bodies. Single cells were carefully isolated from embryoid bodies collected from ascites, and using 
glass capillary tubes, researchers transplanted single cells into 1790 mice, resulting in 43 
successful engraftments of teratocarcinoma. This set of experiments provided some of the earliest 
evidence that single cells can function as CSCs and demonstrated that EC is functionally the CSC 
of teratocarcinoma43. Continued work with EC laid the groundwork for isolation of embryonic 
stem cells as well as their culture conditions165. The close relationship of ES and EC cells, both in 
a historical context and in morphology and pluripotency, supports the idea that both cells may 
share unique DDR as well.  
Mice with germ cell specific Pten inactivation and simultaneous KrasG12D activation, 
referred to as gPAK mice, were introduced in Chapter 2. When treated with cisplatin, or a 
combination of bleomycin, cisplatin, and etoposide, tumor-bearing mice had increased survival 
and reduced tumor burden. Importantly, the EC component of the teratocarcinomas of treated mice 
was greatly reduced in comparison to the untreated tumors (Fig 1.6E). We hypothesize that a 
hypersensitivity of EC cells underlies the increase in survival of cisplatin treated mice within our 
model, and contribute to the high cure rates of TGCTs in people. To test the response of EC cells 
in a more controlled environment, we established two cell lines from teratocarcinomas of this novel 
mouse model. Both cell lines retained their tumor-propagating phenotype and pluripotency 
markers similar to their in vivo counterparts. We show that they also appear to retain a 
hypersensitivity to cisplatin-induced damage, and can function as a powerful reagent in elucidating 
the unique DDR underlying the exceptional response to genotoxic chemotherapies among TGCTs. 
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3.2 RESULTS 
Derivation of embryonal carcinoma cell lines that retain cancer stem cell properties. Because EC 
cells are present in small isolated clusters, surrounded by vast amounts of heterogeneous teratoma 
tissues, it is difficult to study specific EC cellular responses to drugs in vivo. We sought to culture 
in vitro cell lines derived from our genetic model of teratocarcinomas, described in Chapter 2, to 
better characterize the unique mechanisms of EC cell response to genotoxic chemotherapies. 
Tumors collected during necropsy were mechanically disaggregated and placed in digestion media 
with collagenase on a shaker at 37C to generate a single cell suspension. These cells were then 
plated at decreasing cell concentrations, passaged upon confluency, and monitored for EC colony 
formation. ROCK inhibitor Y-27632 was used in initial passages as it is known to reduce 
disassociation-induced apoptosis in human embryonic stem cells225. Mouse leukemia inhibiting 
factor (LIF) was included in EC culture media as its ability to prevent differentiation of ES cells 
in vitro has long been characterized, and some studies show similar benefits for EC cells226,227. 
Two cell lines, EC3 and EC11, were successfully derived from primary gPAK tumors using these 
methods (Fig. 3.1A). Both cell lines continued consistent growth following 40 passages and 
formed colonies similar to those reported for ES cells and some mouse EC lines. Upon 
subcutaneous injection into the flanks immunocompromised mice, as few as 100 EC3 and EC11 
cells were sufficient to generate tumors within two weeks, thus suggesting that they retained their 
CSC properties (Table 3.1). The tumors were characterized as teratocarcinomas histologically 
similar to primary tumors including retention of the OCT4 expressing EC cell populations (Fig. 
3.1B). Retention of these CSC phenotypes suggests the de novo EC lines cells harbor similar 
pluripotency and self-renewal networks despite exposure to an artificial in vitro environment. The 
EC3 line was generated from a gPAK mouse harboring an OCT4-GFP transgene which expresses 
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GFP in any cell that expresses OCT4, thus allowing identification of EC cells versus their 
differentiated counterparts in vitro (Fig. 3.1E). 
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Figure 3.1 Embryonal carcinoma cells isolated from gPAK tumors retain CSC phenotype. 
Representative brightfield images of EC colonies appeared from heterogeneous plating of 
disaggregated murine teratocarcinomas (A). Upon engraftment in immunocompromised mice, 
cells formed teratocarcinoma similar to primary tumors, including maintenance of EC, as shown 
by representative sections stained with H&E and for OCT4 (B). After two weeks of exposure to 
1x10-5M of Thioridazine, EC cells differentiated into a more flattened cell morphology which grew 
as a monolayer (C) and exhibited a reduced expression of OCT4 as evidenced by protein lysate 
analysis (D). EC3 cells exposed to 1x10-7M of retinoic acid for approximately two weeks also 
differentiated, and lost OCT4 expression as shown by loss of GFP expressed under the control of 
the OCT4 promoter (E). 
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Thioridazine induces EC cells to differentiate and lose pluripotency. To determine if EC cells are 
hypersensitive to cisplatin in the same way other pluripotent cells are, well-matched, differentiated 
controls derived from the pluripotent EC lines were necessary. Although very little is known about 
EC cell DDR, both ES, and iPS cells have been well studied. It is reasonable to expect traits found 
to convey ES and iPS cell genotoxin hypersensitivity will be shared by other pluripotent cells, 
including EC cells. Storage of primed BAX at the golgi, and a reduced or non-existent G1/S 
checkpoint are two major pro-apoptotic responses to DNA damage that are unique to these 
pluripotent cells, both of which are lost upon differentiation125,127,129. To generate well-matched 
controls, the EC cell lines were exposed to 1x10-5M of thioridazine (Fig. 3.1C). Differentiated cell 
lines derived from EC3 and EC11 will be referred to as TR3 and TR11 respectively. After about 
two weeks of constant exposure to thioridazine, the majority of cells in the culture grew as a 
homogeneous monolayer with very few persistent EC colonies (Fig. 3.1C). OCT4, a transcription 
factor necessary to maintain pluripotency, was substantially reduced in both TR cell lines (Fig. 
3.1D). EC3 cells were separately exposed to 5x10-7M of retinoic acid (RA) which also induced 
differentiation (Referred to as RA3 cells) as evidenced by loss of EC colonies and OCT4 
expression, although several persistent EC colonies remained after all differentiation attempts with 
RA (Fig. 3.1E). The ability to propagate tumors is another hallmark of CSCs, and as few as 100 
EC3 or EC11 cells subcutaneously transplanted into immunocompromised mice were able to 
generate teratocarcinomas within 2 weeks (Table 3.1). However, the differentiated cell lines 
formed tumors at reduced frequency, and the tumors that did form did so with increased latency. 
Importantly, because all differentiated cell cultures had some remaining EC cells, as evidenced by 
the faint OCT4 band (fig. 3.1D), it is likely that the rare surviving EC cells were sufficient to 
propagate the tumors rather than the more differentiated cells forming tumors. This is supported 
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by the fact that those tumors which formed from mostly differentiated cells still contained OCT4 
positive EC cells at endpoint. 
 
EC cells exhibit greater sensitivity to cisplatin-induced damage than their respective differentiated 
cell lines. As described in Chapter 2, tumors that formed in gPAK mice were sensitive to genotoxic 
chemotherapies (Fig. 2.6A). Importantly, the EC populations within tumors were significantly 
reduced after treatment compared to those in untreated controls (Fig. 2.6C,D) suggesting EC cells 
are particularly sensitive to cisplatin compared to the more differentiated tissues that comprise the 
teratoma. Similarly, the lack of EC cells in post-treatment human teratocarcinomas, despite 
residual teratoma tissue that requires surgical resection, also suggests EC hypersensitivity 
compared to the differentiated teratoma components172,173. To test if the process of differentiation 
diminished chemosensitivity in the TR3 and TR11 cell lines, we tested cell survival following a 
1-hour exposure to either 6ug/mL or 12ug/mL of cisplatin.   
Following 6ug/mL of cisplatin, both EC3 and EC11 cells had disruption of colonies demonstrated 
by an increase of loosely adhered cells surrounding the colonies and significantly reduced cell 
survival at 24 and 48 hours post-treatment compared to differentiated controls. EC3 cells tend to 
grow as colonies as well as flat monolayers reminiscent of cell morphology in some human EC 
lines regardless of treatment status228,229. TR3 and TR11 showed no significant changes in cell 
morphology, and only a moderate loss of cell survival after 6ug/mL cisplatin. Following 12ug/mL 
of cisplatin, both EC cell lines showed a dramatic loss of EC colony formation, and at 48 hours 
very few cells remained in colony or monolayer form as evidenced by representative images and 
cell survival counts. The differentiated TR cells showed a slight reduction in survival at 24 hours 
post 12ug/mL cisplatin, while only TR11 had a large reduction in viable cells 48 hours after the 
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higher dose of cisplatin. While the higher dose suggests the differentiated cells don’t show a 
survival reduction 24 hours after treatment, TR11 cells did have reduced survival at 48 hours. The 
6ug/mL dose may induce apoptosis in the EC cells at a significantly higher rate at both measured 
timepoints, indicating a heightened sensitivity of EC cells compared to the differentiated controls 
which are similar to what was observed in vivo following cisplatin treatment (Fig. 2.6). 
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Table 3.1 
 
 
  
Number of cells 
injected Injection sites
Tumors 
formed Mean latency
10,000 1 1 11
1,000 3 3 16
100 4 3 13
10 4 2 46
EC3-RA 1,000 2 1 21
EC3-TR 1,000 4 1 20
1000 2 2 7
100 2 2 14
EC11-TR 1,000 4 4 20
EC3
EC11
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Figure 3.2 Established EC cell lines retain hypersensitivity to chemotherapy compared to 
differentiated counterparts. Representative brightfield images of untreated EC3, EC11, TR3, 
and TC11 compared to cells 24 and 48 hours post-treatment of 6ug/mL (A) and 12ug/mL (B) of 
cisplatin. Quantification of percent cell survival calculated by trypan blue negative cells manually 
counted on a hemocytometer, normalized to untreated controls, after 6ug/mL cisplatin (C) or 
12ug/mL cisplatin (D). Significantly fewer EC3 and EC11 cells survived compared to their 
differentiated counterparts at 24 (p=0.045 and p=0.0028 respectively, Students t-test), and 48 
(p=0.049 and p=0.01 respectively, Students t-test), when treated with 6ug/mL cisplatin. At 
12ug/mL, the differentiated cells also showed high sensitivity and the differences between EC and 
TR cells were not as significant. 24 hours post treatment (EC3 p=0.49 and EC11 p=0.0023, 
Students t-test), and 48 hours post treatment (EC3 p=0.0495 and p=0.087 respectively, Students t-
test) at 12ug/mL. 
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3.4 DISCUSSION 
We have shown that EC cells from our novel mouse model of teratocarcinoma can be cultured 
while retaining their CSC and chemosensitive phenotypes (Fig. 3.1,3.2). Both cell lines grew 
rapidly and formed colonies, similar to ES and other EC lines. Interestingly, compared to EC11, 
EC3 colonies appeared less uniform, despite being derived from the same model. These differences 
may reflect alterations introduced during the establishment of the cultures or innate differences 
from the respective primary tumors, but regardless appear to be stable phenotypes of the two lines. 
These differences emphasize the need to isolate additional EC lines as well as caution when 
interpreting data from previous EC lines that have been propagated in vitro for decades. TERA2, 
NTERA2.cl.D1, and P19 are commonly used human EC cells, which exhibit differential growth 
and other phenotypes that may reflect their artificial environment more than differences in the 
original tumors228,229. A recent in vitro analysis concluded that in some established EC cell lines, 
reduced homologous recombination repair is responsible for their chemosensitivity230. Additional 
evidence based on in vivo observations and in vitro studies of TGCT chemosensitivity suggests 
the underlying mechanisms of sensitivity are an active system that is considerably more complex 
in vivo, with an interplay between DDR and pluripotency transcriptional networks231. 
  Despite differences between EC3 and EC11, they both shared chemosensitivity (Fig. 3.2). 
This phenotype was also shared by all treated primary tumors of the gPAK model from which 
these cell lines were derived, suggesting the underlying mechanisms of sensitivity will also be 
similar (Fig. 2.6). It also needs to be determined if the EC cells surviving after 6ug/mL cisplatin 
remain proliferative, or senesce. Indeed, EC cells are known to have a robust P53 mediated 
senescence and apoptotic response to damage169,232. Comparing mRNA and protein level changes 
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following cisplatin treatment, between the EC and matched TR lines, will allow the elucidation of 
the underlying mechanisms of this chemosensitivity. High levels of cytosolic P21 expression were 
shown to be prognostic of chemoresistant EC in humans, likely avoiding apoptosis by inducing 
cell cycle arrest123. Comparing P21 expression between our chemosensitive EC lines compared to 
their differentiated counterparts would determine if significantly lowered P21 expression plays a 
role in EC sensitivity123. Protein and gene expression analysis will also establish if these EC cells 
exhibit any predicted mechanisms of chemosensitivity associated with other pluripotent cells, such 
as lacking G1 checkpoint or harboring primed BAX at the golgi, as is reported in mouse embryonic 
stem cells127. The rapid proliferation of EC cells compared to the relative quiescence of most 
somatic CSCs, may also play a role in their heightened susceptibility to DNA damaging 
chemotherapeutics. As discussed in Section 1.3, aside from DDR and apoptotic pathway genes, 
there are other determinants of chemosensitivity including the ability of cells to pump drugs out 
of the cell against their concentration gradient, drug detoxification, and drug target manipulation, 
which have yet to be explored as a basis for embryonal carcinoma chemosensitivity. We will also 
continue to expand this library of cell lines, making it an increasingly useful reagent for ourselves 
and other researchers. 
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3.5 METHODS 
gPAK TGCT primary culture. gPAK testicular tumors were isolated from gPAK untreated and 
disaggregated with 2 mg/mL Collagenase A (Roche) in serum-free DMEM with penicillin, 
streptomycin, and gentamycin at 37C for approximately 1 hour, shaking. Cells were then passed 
through a 40 µM filter to remove large clumps, pelleted at 1.5 x g for 5 minutes, then suspended 
in DMEM or DMEM + 10% FBS, + 1x LIF (ORF Genetics), + 10 µM ROCKi (Selleckchem) and 
plated with these media conditions. Both EC lines were maintained in this media without ROCKi 
over up to 70 passages. The media was replaced every day and cells were passaged at a 1/10 split 
every other day. To induce differentiation, cells were incubated with either 1x10-7M of retinoic 
acid (Sigma) or 5x10-5M of thioridazine (Sigma). 
 
Transplantation of EC3 and EC11 cells. Plated cells were washed with 1X sterile PBS and then 
exposed to trypsin at 37C until detached from the cell culture plate. Cells per mL were calculated 
by hemocytometer before pelleting at 1.4g for 4.5 minutes. 10, 100, or 1000 cells were suspended 
in 100 µl PBS and stored on ice for transportation to mouse facilities. Just before injection, 100 
µL of cells were mixed with 100 µL matrigel (BD Biosciences) in a 1 mL syringe with an 18 gauge 
needle and injected subcutaneously into the flanks of NOD.CB17-Prkdcscid/J mice. Mice were 
monitored weekly for initial tumor formation and euthanized when the tumors reached 
approximately 2cm in diameter. 
 
Histology and immunohistochemistry. Tissues were fixed overnight in Bouin’s fixative at 4C or 
in fresh 4% paraformaldehyde (Sigma-Aldrich) in PBS at room temperature, embedded in wax, 
and sectioned at 5 µm. Immunohistochemical staining for OCT4 (Abcam ab19857, 1:1000) was 
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done using heat-mediated antigen retrieval in EDTA, pH 8.0. After rehydration and antigen 
retrieval, primary antibody was incubated overnight followed by biotinylated secondary antibody 
and then streptavidin HRP conjugate (Invitrogen Histostain SP) incubations at room temperature. 
Finally, positive cells were visualized with DAB (Invitrogen) and counterstained with 1:1 
hematoxylin (Fisher CS401-1D) solution before dehydration.  
 
Chemotherapy treatments. Cisplatin (Sigma P-4394) was dissolved in 0.9% NaCl to a 
concentration of 1 mg/mL and stored at room temperature for up to 1 month. To treat cells, a 
master mix of media was freshly prepared of the desired working cisplatin concentration and then 
immediately used to replace the current media. After 1 hour of cisplatin exposure, the media was 
replaced by fresh cisplatin free media. 
 
Western blot analyses of OCT4. Cells were collected in cold PBS, pelleted and resuspended in to 
IP lysis buffer and incubated for 30 minutes on ice, then centrifuged for 25 minutes at high speed 
at 4C. The lysate was then collected with the supernatant and protein concentrations were 
measured using Bradford reagent OD matched to a standard curve. 15ug of protein was loaded 
into a 12% SDS-PAGE gel, then transferred to a nitrocellulose membrane. The membrane was 
incubated with OCT4 (Abcam ab19857, 1:1000) overnight at 4 degrees and visualized using a 
Versa Doc Imaging System.   
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CHAPTER 4 
Conclusions and future directions 
The findings of this dissertation support the hypothesis that EC cells function as CSCs and that 
their unique response to platinum-based genotoxic drugs underlies the exceptional 
chemosensitivity of these malignancies. These data mostly came from experiments utilizing the 
novel gPAK TGCT mouse model developed by the Weiss lab, which initiated germ cell 
tumorigenesis by inducing germ cell specific Pten inactivation with simultaneous induction of 
constitutively active KrasG12D (Fig. 2.1A). The teratocarcinomas that arose within this mouse 
model were highly representative of human GCNIS-derived mixed TGCTs comprised of EC and 
teratoma components. The murine teratocarcinomas had histological similarities to the human 
disease, including an EC component expressing the same diagnostic pluripotent stem cell markers 
expressed in the human disease (Fig. 2.2A).  
In humans, these malignancies are believed to initiate during embryogenesis, only 
presenting later in life as a result of additional changes that facilitate cancer cell growth and spread. 
Within the context of the gPAK model, the data showed that malignant transformation of germ 
cells only occurred during embryonic development (Fig. 2.3B), while the same oncogenic 
activation caused aberrant proliferation followed by germ cell death when induced by postnatal 
Stra8-cre expression (Fig. 2.4F, Fig 2.5A,E). The data presented also showed that EC cells 
functioned as the CSC of these teratocarcinomas (Fig. 2.S1, Fig. 2.S2) which support conclusions 
from previous studies utilizing rarely occurring spontaneous teratocarcinomas from 129 inbred 
mice43. Importantly, the teratocarcinoma in this model showed in vivo sensitivity to combined 
treatment with bleomycin, etoposide, and cisplatin administered at doses comparable to the current 
standard of care for human TGCTs (Fig. 2.6A). Significant sensitivity was also observed to 
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cisplatin when administered alone, emphasizing the pivotal role of platinum-based drugs in 
treatment. Sensitivity was reflected in significantly smaller primary tumors and increased survival 
in treated mice, but most interesting was the loss of EC cells that accompanied these responses 
(Fig. 2.6B,C).  
The EC hypersensitivity was confirmed by comparing cell survival in response to cisplatin 
treatment of EC cultured cells derived from this model compared to differentiated cells also 
derived from the gPAK model (Fig. 3.2B,D). The data presented here are the first evidence that 
murine teratocarcinoma, and specifically their CSCs, respond well to genotoxic chemotherapies in 
vivo. Because EC is the established CSC of teratocarcinoma, it is very pertinent that these cells 
were depleted in response to treatment. The overall findings of this thesis indicate that the 
heightened chemosensitivity of TGCT CSC plays a major role in the overall high cure rate among 
patients with TGCTs. 
 
4.1 Characterizing a relevant and reliable model of malignant testicular germ cell tumors 
As referenced in the introduction, several mouse models of TGCTs exist233. However, these 
models are representative of prepubertal-teratomas in humans and make poor models of the 
malignant TGCTs that comprise the majority of germ cell tumors. Although 25% of gPAK mice 
did not develop tumors, all TGCTs that did arise in this model are malignant teratocarcinomas that 
included an EC component. Because of this, the tumors which formed in the gPAK model are 
highly representative of GCNIS derived human TGCTs. This model has proven permissive for 
studying bulk EC cell response to genotoxic chemotherapeutics both in vivo and in vitro, allowing 
for characterization of drug response timing (Fig. 3.3A-D). Additional work is still needed to 
understand the mechanisms by which EC cells respond to genotoxic chemotherapies as part of an 
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ongoing effort to elucidate potential mechanisms that confer their amazing chemosensitivity at the 
cellular level.  
 
4.2 Understanding of germ cell susceptibility to oncogene-induced malignant transformation 
Germ cells are among the most precious and unique cells within the adult body. While entirely 
dispensable to an individual’s survival, viable germ cells are necessary for the survival of a species. 
Without their highly conserved developmental pathways, and enhanced genomic protection, germ 
cells would be at an increased risk of passing deleterious mutations to offspring. However, little is 
currently known about these protective mechanisms at most stages of development13. Our findings 
led to a model of differential response from germ cells when confronted with prenatal versus 
postnatal oncogenic activation (Fig. 2.S7). This disparate monitoring of germ cell integrity 
suggests that only limited developmental timepoints exist during which germ cells are susceptible 
to oncogene-induced malignant transformation. The isolated prenatal activation of Stra8-cre 
appears limited to around E12.5 making it the likely timepoint when gPAK tumors first initiation. 
This unexpected activation of Stra8-cre could be explained by the global reprogramming events 
that occur in germ cells around E12.5. Immediately following migration at E11.5, the second wave 
of epigenetic reprogramming results in erasure of specific histone modifications, histone variant 
swapping, and DNA demethylation, all of which is necessary to restore totipotency to the germ 
cells234,235. This sudden change in gene expression could allow the rare expression of Stra8-cre 
which ultimately drives the oncogene activation in the gPAK model. In mouse strains susceptible 
to teratoma formation, endogenous Stra8 is also expressed around E12.5 in male mice which could 
allow those cells germ cells to continue proliferating rather than undergo mitotic arrest, and may 
be a molecular switch of malignant transformation of those germ cells84. We cannot determine if 
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the early Stra8-cre and Stra8 expression is related, or if the Stra8-cre expression is an artifact due 
to the use of a partial Stra8 promotor. This expression occurs around E13.5 and corresponds with 
RA production, and it is, therefore, possible that rare germ cells fail to express CYP26 sufficiently 
causing an inability to degrade RA, the accumulation of which would facilitate expression of Stra8, 
and Stra8-cre21. 
 While oncogenic events in prenatal germ cells lead to malignant transformation, the same 
oncogenic events lead to germ cell apoptosis when they occur postnatally (Fig. 2.4,5). This change 
in response to oncogene activation supports the concept of an early window of susceptibility to 
malignant transformation hypothesis. Beyond that window, it is unclear what changes have 
occurred to alter susceptibility. We did not observe constitutive activation of yH2AX in early 
gPAK tumors, which suggests, similar to human TGCTs and contrary to human somatic cancers, 
there is very little activation of DDR during early tumorigenesis of gPAK TGCTs (Fig. 2.2E,F)92. 
Postnatal oncogene activation in germ cells, however, could result in increased replication stress 
and meiotic defects. That damage could lead to checkpoint activation similar to that of many 
somatic cells, ultimately inducing apoptosis due to the low tolerance for DNA damage in germ 
cells88. There is relatively little known about the germ cell response to oncogenic events at any 
stage of development, and these data provide some insight. The exact mechanisms that prevent 
malignant transformation in later germ cells are entirely unknown and represent a potentially 
significant research direction using this mouse model. 
 It is not clear why neither Stra8-cre mediated Pten inactivation nor KrasG12D activation 
alone is sufficient to cause germ cell tumorigenesis at an appreciable rate (Fig. 2.1A). While both 
of these oncogenic events are sufficient to induce tumorigenesis in many somatic cells, incidence 
varies dependent on the tissue236. There is evidence that the presence of Pten plays a major role in 
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facilitating mitotic arrest. Inactivation of Pten leads to increased iPS transformation in vitro, 
suggesting a role in transcriptional reprogramming and malignant transformation237. Conditional 
inactivation of Pten in earlier PGCs by TNAP/cre resulted in failed mitotic arrest and 100% 
teratoma formation in 129 inbred mice83. Conditional inactivation of Pten with Stra8-cre only 
produced tumors in 20% mice, which would likely be a higher percentage if early cre mediated 
excision occurred in more germ cells around E12.5. Together, this adds support to the idea that 
gPAK tumors only initiate around E12.5 from the sporadic Stra8-cre activation, and not from the 
more widespread activation that happens postnatally.  Pten’s role in ensuring mitotic arrest could 
explain why germ cells with oncogenic Kras activation never underwent malignant transformation. 
However, because all tumors in our model were teratocarcinoma, rather than teratoma, regardless 
of Pten or combined Pten/Kras mutations, the timing likely plays a significant role in determining 
the path of tumorigenesis. Furthermore, the use of both Pten and Kras alterations may sufficiently 
increase the chances of cellular reprogramming needed for malignant transformation within a very 
short window of time before mitotic arrest.  
 
4.3 The basis of TGCT chemosensitivity and implications for CSC-targeted therapy 
Our results suggest that the amazingly high survival rates achieved when treating TGCTs with 
platinum-based combination chemotherapy are partly due to the presence CSCs with an extremely 
sensitive damage response. Within this model, the CSCs are depleted upon treatments comparable 
to the human standard of care and the depletion occurs along with significantly increased survival 
and reduced tumor burden. Potentially, if tumors were surgically removed from the mice following 
treatment, as they are in humans, higher murine survival rates may have been achieved.  
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Our data suggest a rapid increase in damage following treatment that quickly induces apoptosis in 
EC cells (Fig. 2.7, 3.3), but many of the differentiated cells of the teratoma appear less sensitive 
based on their persistence in vivo and lack of strong apoptotic response in vitro (Fig. 2.6D, 3.2A-
D).  
These findings are similar to tumors post treatment in humans, which often have surviving 
teratoma tissue, devoid of EC, when it is surgically removed172,173. Additionally, gPAK EC cells 
persist if untreated, and have a relatively high expression of P53 which are both phenotypes of 
human EC and suggest similar self-renewal and DDR mechanisms30. It is important to note that 
seminomas comprise approximately half of all TGCTs but are homogeneous, and do not yet have 
an identified CSC population. However, they have a slightly better prognosis following genotoxic 
treatment. One potential explanation for this is that because seminoma cells express many 
pluripotent transcription factors and have a PGC appearance, most cells may share the same 
heightened apoptotic response to induced DNA damage as our data shows for EC cells. Additional 
work is needed to understand the mechanisms of sensitivity in our model and further validate the 
findings in human PDX models of EC and seminoma. 
 The discovery of a chemosensitive CSC within a solid cancer that is considered curable is 
highly relevant to the CSC field. The ultimate goal of efficiently targeting CSCs in otherwise 
incurable cancers is to render them curable. In our model, we have demonstrated that the standard 
of care treatment efficiently targets the CSC of TGCTs, which was a devastating and incurable 
disease before the advent of these drugs. In this context, the efficacy of TGCT treatment suggests 
that finding ways to eliminate CSCs in somatic cancers may result in similar success stories. 
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4.4 Future directions. 
This dissertation work has been focused on the response to therapies known to be efficacious for 
treating human TGCTs. However, these drugs are toxic to all cells, and while they can cure TGCTs 
they also cause serious chronic illnesses, such as infertility, which has led to an interest in less 
toxic treatments162,238. Because gPAK murine TGCTs are representative of GCNIS derived human 
TGCTs, this model could provide an ideal system for screening alternative targeted or 
differentiation therapies. Differentiation therapy is already an attractive alternative for targeting 
chemoresistant CSCs within a variety of somatic cancers239,240. The goal of these therapies is to 
induce differentiation within the CSC population without harming normal stem cell pools. Our 
data shows that retinoic acid and thioridazine can be effective inducers of differentiation of EC 
cells in vitro, resulting in loss of tumor-propagating potential (Fig. 3.1A,B). Vitamin D is 
implicated as a potential differentiation drug for germ cell tumors as well, but the studies rely on 
long-term cultured EC cells241. Although in vitro screening for anticancer drugs is a powerful tool 
in preclinical testing, cells grown for long periods of time show deviations from in vivo tumors, 
leading to results that are not necessarily biologically relevant (Fig. 4.1). Potential alternative drugs 
like those mentioned could be tested in vitro in low passage gPAK derived EC cultures before 
being tested in vivo using the gPAK model mice. Because of this, the gPAK model holds great 
promise for both understanding the biological mechanisms of these tumors, and for uncovering 
less toxic candidate drugs for TGCT treatment. 
Furthermore, we have made novel and exciting discoveries about the timing of oncogene-
induced malignant transformation of germ cells. Our data clearly show that protective mechanisms 
prevent postnatal oncogenic events in germ cells from inducing tumorigenesis, while also showing 
evidence that tumorigenesis initiates at E12.5 in our model. However, this timing is only the 
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earliest we can describe for our model, but we can not rule out additional susceptibility between 
E12.5 and birth. Our results also do not show at what exact timepoint germ cells become immune 
to the malignant transformation from these oncogenic events. A temporally controlled, germ cell 
specific, CreER would allow separation of timing and oncogenic pathways to dissect the exact 
window of susceptibility. This data would help elucidate what protective mechanisms allow some 
oncogenic events to be dramatically more efficient at transforming germ cells than others. 
Currently, we have incorporated the conditional oncogenic alleles of Pten and Kras described 
above, with the tdTomato reporter, also described above. This additional tracking of early and late 
malignant cells will allow us to observe the earliest signs of germ cell tumorigenesis in vivo, and 
also determine DDR and changes in transcriptional markers relative to non-Stra8-cre expressing 
germ cells at that time. These data will provide additional insight into the timing malignant 
transformation susceptibility as well as a better understanding of initial malignant changes that 
occur in these initiating tumors, thus helping better understand their seemingly disparate path of 
tumorigenesis compared to most somatic cancers. 
The next step for these studies is to further elucidate the mechanistic basis of the DDR 
following cisplatin treatment as well as other genotoxic drugs. P21 expression was shown to be 
prognostic of chemoresistant EC in humans, likely avoiding the apoptotic response to cisplatin-
induced damage through cell cycle arrest, resulting in a refractory response to the treatment123. It 
is not yet known if cytosolic P21 levels are abnormally low in chemosensitive cells, but quantifying 
P21 in our EC lines compared to differentiated TR3 and TR11 cell lines will be informative. It is 
also not known if these EC cells will exhibit any predicted mechanisms of chemosensitivity such 
as lacking G1 checkpoint or harboring primed BAX at the golgi, as is reported in mouse embryonic 
stem cells. Elucidation of these phenotypes within the context of this model requires further 
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experiments to examine cell cycle checkpoint activation, lysate analysis, and response kinetics 
following exposure to cisplatin discussed further in Chapter 3. 
 Additionally, it is important to look for response pathways that have yet to be predicted as 
the underlying cause of chemosensitivity in TGCTs. To do this, genome-wide analysis of mRNA 
expression is the next immediate step of this study. Previous studies have sought to identify 
determinants, and the underlying mechanisms, of cisplatin-resistant cancer cells using high-
throughput RNA sequencing, but no such studies exist to identify hypersensitivity of EC cells to 
chemotherapy242,243. Beyond the expected pathways of cisplatin sensitivity, this method may reveal 
unexpected pathways that to help unravel the crosstalk between the pluripotent transcriptional 
network and DDR. This unique approach could lead to a better understanding of these mechanisms 
and may lead to entirely novel targets for CSCs in somatic cancers.  
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APPENDIX 
APPENDIX A. PATIENT DERIVED XENOGRAFTS OF CANINE LYMPHOMA 
A.1 INTRODUCTION 
Testing anti-cancer drugs within meaningful systems, and a better method for developing 
personalized therapies have been a growing focus of cancer research for decades244. Drug response 
screening with well-established cell lines, such the NCI-60 collection, plays a critical role in drug 
development as well as identifying predictive response markers and understanding the mechanisms 
of those responses245. However, cells grown under artificial conditions are known to develop 
mutations and gene expression changes that make them less representative of in vivo malignancies 
(Fig. 4.1). Three-dimensional culture is a growing field that seeks to combine the high-throughput 
power of two-dimensional culture with a more biologically relevant environment and holds great 
promise but does not fully represent in vivo systems246. Currently, there is great interest in the use 
of patient-derived xenografts (PDX) to avoid the artificially induced aberrations that can occur 
with in vitro studies, and provide a robust model for drug screening and tumor biology247. PDX 
models also provide a more representative genetic profile compared to Genetically Engineered 
Mouse Models (GEMMs) which usually form disease with one or two specific genetic drivers. 
The more realistic genetic profiles of the PDX malignancies may result in more translatable drug 
responses248. Ideally, PDX lines are established using fresh tissue from a patient malignancy that 
is immediately engrafted into an immune compromised mouse, introducing as few potentially 
selective pressures as possible in hopes of maintaining the initial tumor biology.  
Following mammary cancer, lymphoma is the most common malignancy among dogs, with 
diffuse large B-cell lymphoma (DLBCL) (A type of Non-Hodgkin’s lymphoma) being the most 
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common aggressive lymphoma in dogs249,250. DLBCL is a heterogeneous disease but can be 
categorized by molecular markers into two main types; activated B-cell (ABC) and germinal 
center B-cell (GCB) in the human disease, the latter of which carries a much better prognosis. 
Those same molecular markers are not diagnostic of canine DLBCL, but there are many aspects 
of canine DLBCL that are similar to human DLBCL which correlate to the ABC and GCB 
subgroups in humans suggesting possible similarities in drivers, cell of origin, and overall 
genetics between the DLBCL that arises in the two species253. Canine cancers have been 
proposed as a valuable model for human cancers, the study of which has benefits for both 
species251,252. Both humans and canines are treated with CHOP as frontline care for DLBCL, 
while humans also receive the anti-CD20 antibody rituximab (R-CHOP). Approximately 65% of 
Non-Hodgkin’s lymphoma human patients will survive past ten years leaving an intense interest 
in new drugs for treating the disease in humans and canines that fail to respond. Despite a large 
amount of research aimed at studying these cancers, therapy response remains difficult to 
predict, and further research utilizing PDX models of the disease may help elucidate better 
predictive factors249. Establishing canine lymphoma PDX models will not only help find new 
treatments for the canine disease but due to the similarities in humans this research could also 
uncover new treatments for human patients as well. Here we describe results in an ongoing effort 
to establish the first patient-derived xenografts from separate canine lymphoma patients. 
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A.2 CREATION OF PDX MODELS FOR CANINE LYMPHOMA 
After receiving owner consent, patients underwent removal of lymphoma tissue which was 
immediately processed according to the protocol described in Methods, Section A.3. Nine total 
patients have been enrolled in this program (Table A.1) with a detailed listing of individual 
engraftment attempts enumerated in Table A.3. Two successful PDX lines have been established 
using these methods (Figure A.1, A.4) and have been continuously propagated in mice, while 
viable frozen samples have been stored with support from the Cornell Biobank, along with samples 
for later histological, DNA, RNA, and protein investigations. 
 The initial engrafted PDX, referred to from here as 14298, came from a neutered male 
Rottweiler patient at the Cornell Animal Hospital (Table A.1). The original diagnosis was made 
based on flow cytometry profile, which showed no major shifts in lymphoma markers after initial 
passages as a PDX in mice (Table A.4, Figure A.2). One notable change in the PDX samples was 
increased expression of CD3 in initial and secondary passages compared to analysis of the primary 
tumor. CD3 is associated with T-cell development and T-cell lymphoma, but not B-cell lymphoma 
as this tumor was originally characterized. The implications of this increased expression are 
currently unclear, and we will monitor for sustained expression at higher passages. Histologically, 
the primary tumor and initial passages were similar large B-cell lymphoma samples (Fig. A.3). 
 The second engrafted PDX, referred to from here as 15810 (Table A.1), grows at 
approximately twice the rate of 14298, although both engrafted PDX lines still require more 
accurate growth rate analysis. This dog was not treated at Cornell Animal Hospital but was 
euthanized there, and the tumor sample was excised immediately after euthanasia. Unfortunately, 
because this dog was not a patient, no flow cytometry data was collected for the primary tumor, 
and the diagnosis of B-Cell lymphoma was made based on immunohistochemistry profile. No 
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substantial changes within the passaged PDX tumors were seen from flow cytometry analysis 
conducted by Cornell diagnostic laboratories (Table A.5, Figure A.5). One finding of note was the 
presence of CD5 and CD25 in first passage tumor indicating an activated phenotype, but these 
markers were absent from second passage tumors. Loss of CD5 after the first passage may indicate 
a loss of activated T-cells transferred with primary tumor tissue. As PDX mouse 15810-101 
became hunched, piloerect and dehydrated necessitating euthanasia, the presence of activated 
CD3+ T-cells in the primary passage may support the hypothesis of graft-vs-host (GVH) disease 
from T-cells transferred from engraftment. Although CD3+ T-cells are not a marker for GVH, the 
NSG host mice are unable to produce CD3+ T-cells254. Alternatively, this change may represent a 
change in expression of tumor cells or a loss of a subpopulation of tumor cells. Histologically, the 
primary tumor and initial passages were similar large B-cell lymphoma samples (Fig. A.6). 
The successful creation of PDX models of canine B-cell lymphoma shows the feasibility of this 
approach. Current efforts are directed at improving the initial success rate of engraftment from 
primary tumor by attempts to avoid GVH disease by titrating the initial amount of tissue injected 
as well as encapsulating tumors in a semi-permeable membrane to prevent the escape of T-cells 
that are responsible for GVH. Treating mice with T-cell targeted immunosuppressant cyclosporine 
is another option for reducing the risk of GVH. Using the two currently established PDX lines, we 
will begin trialing different therapies to identify novel and more efficacious therapies against these 
malignancies in the hopes of finding better treatments for canine lymphoma patients, and 
potentially humans. 
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Table A.1 List of patients from which primary tumors were collected 
 
 
 
Collection date Bank ID Case ID Breed Sex Tumor type
3/25/2015 13915 236436 Australian Shepherd Neutered male T-cell lymphoma
4/3/2015 13972 236607 Golden Retriever Spayed female B-cell lymphoma
6/12/2015 14298 238033 Rottweiler Neutered male B-cell lymphoma
7/15/2015 14691 238629 Mixed breed dog Neutered male B-cell lymphoma
8/4/2015 13378 234615 Golden Retriever Neutered male B-cell lymphoma
12/14/2015 15810 242058 Rottweiler Neutered male B-cell lymphoma
1/13/2016 15886 190760 Boston Terrier Spayed female B-cell lymphoma
2/11/2016 16016 243190 Rottweiler Spayed female B-cell lymphoma
8/15/2016 18785 246276 Mixed breed dog Neutered male Pending
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Table A.2 Identifying markers used for flow cytometry analyses of primary and PDX tumors 
(adapted from Tracy Stokol, et al.255) 
 
 
  
Antigen Cell Population
CD14 Monocytes 
CD20 B cells 
CD21 B cells 
CD22 B cells 
CD3 T cells 
CD34 Stem cell 
CD4 Helper T cells, neutrophils 
CD45 All leukocytes 
CD5 T cells 
CD8a Cytotoxic T cells 
MHCII Lymphocytes, monocytes 
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Table A.3 List of PDX mice engrafted with primary or serially transplanted tumor tissue 
 
  
Passage Graft date Source Sample ID No tumor Endpoint
1 3/25/2015 13915 13915-101 6/14/2015
1 3/25/2015 13915 13915-102 1/14/2015
1 3/25/2015 13915 13915-103 4/10/2015
2 5/16/2015 13915-102 13915-201 10/22/2015
2 5/16/2015 13915-102 13915-202 10/22/2015
2 5/16/2015 13915-102 13915-203 10/22/2015
2 5/16/2015 13915-102 13915-204 10/22/2015
2 5/16/2015 13915-102 13915-205 10/22/2015
1 4/3/2015 13972 13972-101 4/27/2015
1 4/3/2015 13972 13972-102 4/30/2015
1 4/3/2015 13972 13972-103 5/5/2015
2 4/30/2015 13972-101 13972-201 6/18/2015
2 4/30/2015 13972-101 13972-202 10/21/2016
2 4/30/2015 13972-102 13972-203 10/21/2016
2 4/30/2015 13972-102 13972-204 10/21/2016
Date of death
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Table A.3 List of PDX mice engrafted with primary or serially transplanted tumor tissue  
 
 
 
 
1 6/12/2015 14298 14298-101 12/10/2015
1 6/12/2015 14298 14298-102 10/1/2015
1 6/12/2015 14298 14298-103 7/24/2015
1 6/12/2015 14298 14298-104 12/28/2015
1 6/12/2015 14298 14298-105 10/30/2015
2 7/24/2015 14298-103 14298-201 10/22/2015
2 7/24/2015 14298-103 14298-202 10/22/2015
2 7/24/2015 14298-103 14298-203 10/22/2015
2 7/24/2015 14298-103 14298-204 10/22/2015
2 10/1/2015 14298-102 14298-205 1/21/2016
2 10/1/2015 14298-102 14298-206 3/16/2016
2 10/1/2015 14298-102 14298-207 3/16/2016
2 10/1/2015 14298-102 14298-208 1/21/2016
2 10/1/2015 14298-102 14298-209
2 10/1/2015 14298-102 14298-210 2/18/2016
2 10/1/2015 14298-102 14298-211 3/31/2016
2 10/1/2015 14298-102 14298-212 3/31/2016
2 12/10/2015 14298-101 14298-213 1/21/2016
2 12/10/2015 14298-101 14298-214
3 1/21/2016 14298-208 14298-304 5/18/2016
3 1/21/2016 14298-208 14298-305 5/18/2016
3 1/21/2016 14298-214 14298-306 5/25/2016
3 1/21/2016 14298-214 (met) 14298-307 6/1/2018
3 1/21/2016 14298-214 14298-308 5/18/2016
3 3/16/2016 14298-207 14298-301
3 3/16/2016 14298-207 14298-302
3 3/16/2016 14298-206 14298-303
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Table A.3 List of PDX mice engrafted with primary or serially transplanted tumor tissue  
  
3 3/31/2016 14298-205 14298-309 8/3/2016
3 3/31/2016 14298-211 14298-310 8/3/2016
3 3/31/2016 14298-205 14298-311 8/3/2016
3 3/31/2016 14298-218 14298-312 8/3/2016
4 5/18/2016 14298-308 14298-401 8/17/2016
4 5/18/2016 14298-308 14298-402
4 5/25/2016 14298-306 14298-403 9/15/2016
4 5/25/2016 14298-306 14298-404 9/15/2016
4 5/25/2016 14298-306 14298-405
4 5/25/2016 14298-306 14298-406
4 5/25/2016 14298-306 14298-407
4 5/25/2016 14298-309 L 14298-408 10/20/2016
4 5/25/2016 14298-309 L 14298-409 10/20/2016
5 8/17/2016 14298-401-T1 14298-501 10/20/2016
5 8/17/2016 14298-401-T1 14298-502
5 8/17/2016 14298-401-T1 14298-503
5 9/15/2016 14298-403 14298-504
5 9/15/2016 14298-403 14298-505
5 9/15/2016 14298-403 14298-506
5 9/15/2016 14298-404 14298-507
5 9/15/2016 14298-404 14298-508
6 10/20/2016 14298-501-T1 14298-601
6 10/20/2016 14298-501-T1 14298-602
6 10/20/2016 14298-501-T1 14298-603
6 10/20/2016 14298-501-T1 14298-604
6 10/20/2016 14298-501-T1 14298-605
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Table A.3 List of PDX mice engrafted with primary or serially transplanted tumor tissue 
 
  
1 7/15/2015 14691a 14691-101 9/7/2015
1 7/15/2015 14691a 14691-102 8/31/2015
1 7/15/2015 14691a 14691-103 8/21/2015
1 7/15/2015 14691a 14691-104 9/3/2015
1 7/16/2015 14691b 14691-105 8/10/2015
1 7/16/2015 14691b 14691-106 8/14/2015
1 7/16/2015 14691b 14691-107 8/14/2015
1 7/16/2015 14691b 14691-108 8/14/2015
2 9/7/2015 14691-101 14691-201
2 9/7/2015 14691-101 14691-202
2 9/7/2015 14691-101 14691-203
2 8/14/2015 14691-106 14691-204 1/9/2016
2 8/14/2015 14691-106 14691-205
2 8/14/2015 14691-106 14691-206
2 8/14/2015 14691-106 14691-207
2 8/14/2015 14691-106 14691-208
1 8/4/2015 13378 13378-101
1 8/4/2015 13378 13378-102 8/31/2015
1 8/4/2015 13378 13378-103 9/2/2015
1 8/4/2015 13378 13378-104
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Table A.3 List of PDX mice engrafted with primary or serially transplanted tumor tissue   
  
1 12/14/2015 15810 15810-101 1/25/2016
1 12/14/2015 15810 15810-102 3/9/2016
1 12/14/2015 15810 15810-103 4/22/2016
2 3/9/2016 15810-102(T3) 15810-201 4/20/2016
2 3/9/2016 15810-102(T3) 15810-202 5/10/2016
2 3/9/2016 15810-102(T3) 15810-203 6/1/2016
2 3/9/2016 15810-102(T3) 15810-204
2 3/9/2016 15810-102(T2) 15810-205 4/20/2016
2 3/9/2016 15810-102(T4) 15810-206 4/20/2016
3 4/20/2016 15810-205 15810-301 6/15/2016
3 4/20/2016 15810-205 15810-302 6/15/2016
3 4/20/2016 15810-205 15810-303 6/8/2016
3 4/20/2016 15810-206 15810-304 6/8/2016
3 4/20/2016 15810-202 15810-305 6/8/2016
3 6/1/2016 15810-203 15810-306 7/18/2016
3 6/1/2016 15810-203 15810-307 7/18/2016
4 6/15/2016 15810-302-T1 15810-401
4 6/15/2016 15810-301-T3 15810-402
4 6/15/2016 15810-301-T3 15810-403
4 6/8/2016 15810-303-T1 15810-404 7/13/2016
4 6/8/2016 15810-303-T1 15810-405 7/13/2016
4 6/8/2016 15810-303-T1 15810-406
4 6/8/2016 15810-305-T1 15810-407 7/13/2016
4 6/8/2016 15810-305-T1 15810-408
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Table A.3 List of PDX mice engrafted with primary or serially transplanted tumor tissue 
 
  
5 7/13/2016 15810-405-T1 15810-501 31-Aug
5 7/13/2016 15810-405-T1 15810-502 31-Aug
5 7/13/2016 15810-407-T1 15810-503 31-Aug
5 7/13/2016 15810-407-T1 15810-504 31-Aug
5 7/13/2016 15810-407-T1 15810-505 10/10/2016
5 7/20/2016 15810-408-T1 15810-506
5 7/20/2016 15810-408-T1 15810-507
5 7/20/2016 15810-406-T1 15810-508
5 7/20/2016 15810-406-T1 15810-509
6 8/31/2016 15810-501-Internal 15810-601 10/6/2016
6 8/31/2016 15810-501-R 15810-602 10/6/2016
6 8/31/2016 15810-503-T1 15810-603 10/6/2016
6 8/31/2016 15810-503-T1 15810-604 10/19/2016
6 8/31/2016 15810-503-T1 15810-605 10/19/2016
6 8/31/2016 15810-508-T3 15810-606 10/20/2016
6 8/31/2016 15810-508-T3 15810-607 10/27/2016
6 8/31/2016 15810-508-T3 15810-608 10/20/2016
7 10/6/2016 15810-601 15810-701
7 10/6/2016 15810-602 15810-702
7 10/6/2016 15810-602 15810-703
7 10/6/2016 15810-603 15810-704
7 10/6/2016 15810-603 15810-705
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Figure A.1 PDX transplant lineage map for patient 14298. After successful engraftment of the 
primary tumor, samples were collected and serially transplanted into multiple mice. Orange 
indicates that sample was analyzed using flow cytometry analysis, while green indicates the tissue 
was stored in liquid nitrogen before transplantation. PDX line from patient 14298 was serially 
transplanted approximately every 3 to 4 months. Tumors arising from frozen tissue had 
approximately one month delay before initial detection, but then appeared to grow at a similar rate 
compared to fresh tissue. Likely due to slow growth and soft tissue consistency, these tumors rarely 
interfere with mouse health, even at larger volumes. 
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Table A.4 Flow cytometry analysis for lymphoma markers on select PDX tumors from 
14298. Flow cytometry analysis of primary canine lymphoma, compared to first, and second 
passages in mice. Report generated by Tracy Stokol and Nicole Belcher of the Cornell diagnostic 
laboratories. Tumors are relatively unchanged, except for the increased expression of CD3 with 
the first and second passage compared to the primary tumor.  Mean Fluorescence Intensity 
(MFI).  
  
Date
Marker % MFI % MFI % MFI % MFI % MFI % MFI
CD4 0 0 Yes Yes Yes Yes
CD8 0 0 0 Weak 0 0
MHCII 100 267 100 169 100 125 100 150 99 175 99 153
CD34 10 35 0 few 2 0.4 0.6
CD3-
conj.
0 0 weak Weak 23 18 40 17
Unconj. 
CD3
ND ND 45 41 weak Weak 42 40
CD5 0 0 0 0 0 0
CD45 100 991 98 239 100 271 100 375 100 382 98 375
CD21 99 108 91 55 97 121 99 239 96 77 95 137
CD22 100 189 97 37 99 64 99 75 100 66 97 83
CD14 0 0 0 0 0 0
CD18 99 74 ND 99 60 100 62 100 70 96 43
CD25 ND ND 93 176 97 159 99 127 99 132
CD28 ND ND Weak Weak slight less
CD94 ND ND 0 0 0
FSC
MHCII+C
D34+
4 ND 2 1 0.4 0.6
627 ND 693 700 652
14298 14298-102 14298-205 14298-205 14298-206 14298-207
6/12/2015 10/2/2015 1/26/2016 1/26/2016 3/16/2016 3/16/2016
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Figure A.2 Flow cytometry data showing increased CD3 from primary and 1st transplant. 
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Figure A.3 First passage PDX and primary canine lymphoma are histologically similar. H&E 
of primary canine lymphoma 14298 (Top Left) and the subsequent serial transplants. 
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Figure A.4 PDX transplant lineage map for patient 15810. After successful engraftment of the 
primary tumor, samples were collected and serially transplanted into multiple mice. Orange 
indicates that sample was analyzed using flow cytometry analysis. PDX line from patient 15810 
was serially transplanted approximately every 4 to 6 weeks. Rarely, these tumors ulcerated 
necessitating earlier than planned transplantation.  
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Table A.5 Flow cytometry analysis for lymphoma markers on select PDX tumors from 15810. 
Flow cytometry analysis of first and second transplants of canine B-cell lymphoma. Primary 
lymphoma came from dog sample that was a warm body necropsy and no FACs analysis was 
performed on the original tumor. Loss of CD5 after the first passage is the only notable change 
and needs to be confirmed at higher passages. Mean Fluorescence Intensity (MFI). 
  
Date
Marker % MFI % MFI % MFI
CD4 0 0 0
CD8 0 0
MHCII 97 44 88 21 91 64
CD34 49 23 30 19 54 48
CD3 0 0 0
CD5 54 28 37 10 0
CD45 100 253 100 181 99 532
CD21 99 233 100 248 100 673
CD22 100 223 99 99 100 365
CD14 0 0
CD18 96 58 99 70 98 87
CD25 92 113 94 129 83 128
CD28 0 0
CD94 0 0
FSC 634 634
CD4+CD8+
MHCII+CD34+
CD5:CD21
CD3:CD5
CD21:CD22
CD4:CD8
CD18:CD45
25*
NA
NA
1:01
NA
1:011:01 1:01
4/21/2016
15810-102 15810-102 15810-206
Initia l  site
758
NA NA
1:01 1:01
NA NA
ND ND
15* 7*
NA NA
3/9/2016 3/9/2016
Suspect met Initia l  site
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Figure A.5 Flow cytometry data showing increased CD3 from 1st transplant to 2nd transplant. 
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Figure A.6 First passage PDX and primary canine lymphoma are histologically similar. H&E 
of primary canine lymphoma 15810 (Top Left) and the subsequent serial transplants. 
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A.3 METHODS 
Tissue preparation and injection. Tissue was collected into DMEM with penncillian and 
streptomycin and stored on ice for approximately one hour after surgery while being delivered. 
Once obtained, samples were minced, and approximately 2mm3 was placed in 1X PBS 
immediately before injection. NSG mice were anesthetized by isoflurane and 2mm3 of tumor 
tissue was injected into the right and left flank using an 18 gauge needle. Mice were monitored 
until tumor burden interfered with mobility or until mouse showed signs of dehydration or poor 
body condition. Tissue from mice was collected under sterile conditions, and serial transplants 
were performed as described above.  
 
Histology. Fresh tissues were fixed in buffered formalin (Fisher) at room temperature for 24 hours, 
embedded in wax, and sectioned at 5 µm. Tissues were stained with Eosin (Fisher) and 1:1 
hematoxylin (Fisher CS401-1D) solution before dehydration.  
 
Flow cytometry. Fresh samples were prepared by gentle mechanical disaggregation and stored for 
up to 24 hours on ice in DMEM containing penicillin, streptomycin antibiotics, and 10% FBS. 
Flow analysis was performed using methods described in Tracy Stokol, et al. (2015)255.  
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